Questions

1. Diagnosis and Temporal Pattern:
   • Acute Bacterial Rhinosinusitis (ABRS).
   • Pattern: "Double sickening" (biphasic illness / acute worsening after initial clinical improvement from a viral upper respiratory tract infection).
2. Bacterial Etiologies:
   • Streptococcus pneumoniae (30–40%)
   • Nontypeable Haemophilus influenzae (30–40%)
   • Moraxella catarrhalis (10–15%)
3. Indication for Imaging:
   • No, imaging is not indicated.
   • Acute bacterial rhinosinusitis is a clinical diagnosis. Plain sinus radiographs have poor sensitivity and specificity (mucosal thickening is indistinguishable from uncomplicated viral URI). CT paranasal sinuses is reserved strictly for suspected orbital (e.g., subperiosteal abscess, orbital cellulitis) or intracranial (e.g., epidural abscess, cavernous sinus thrombosis) complications.
4. Antimicrobial Regimen and Dosing Calculation:
   • First-line agent: High-dose Amoxicillin-Clavulanate (14:1 formulation) to overcome penicillin-resistant S. pneumoniae and beta-lactamase-producing H. influenzae / M. catarrhalis.
   • Target amoxicillin dose: $90\text{ mg/kg/day}$ divided every 12 hours (with clavulanate $6.4\text{ mg/kg/day}$).
     $$ > \begin{aligned} > \text{Daily Amoxicillin Dose} &= 26\text{ kg} \times 90\text{ mg/kg/day} \\ > &= 2340\text{ mg/day} \\ > \text{Per-dose Amoxicillin} &= \frac{2340\text{ mg}}{2} \\ > &= \mathbf{1170\text{ mg/dose}} \quad (\text{given orally twice daily with meals}) > \end{aligned} > $$
   • Duration: 10 days (or 7 days beyond resolution of symptoms).

1. Persistent illness: Nasal discharge (any quality) or daytime cough persisting for $\ge 10$ days without clinical improvement.
2. Severe onset: High fever ($\ge 39^\circ\text{C}$ or $102.2^\circ\text{F}$) and concurrent purulent nasal discharge for at least 3 consecutive days.
3. Worsening course ("Double sickening"): New onset or worsening fever, nasal discharge, or daytime cough following transient improvement of a classic viral URI lasting 5–6 days.

1. Diagnosis:
   • Acute viral bronchiolitis.
2. Diagnostic Investigations:
   • None. Bronchiolitis is a strictly clinical diagnosis. Routine chest radiography, complete blood count, and viral PCR panels are not recommended in typical presentations as they do not alter clinical management and correlate poorly with disease severity.
3. Viral Etiologies:
   • Respiratory Syncytial Virus (RSV, >70% of cases)
   • Human Metapneumovirus (hMPV)
   • Rhinovirus
   • Parainfluenza virus (particularly Type 3)
   • Adenovirus
   • Influenza and Coronavirus
4. Supportive Management Protocol:
   • Oxygen therapy: Humidified supplemental oxygen via nasal prongs to maintain $\text{SpO}_2 \ge 92\%$ (or $\ge 90\%$ per AAP guidelines).
   • Airway clearance: Superficial nasal suctioning before feeds and sleep.
   • Hydration and Nutrition: Nasogastric tube feeding with small, frequent feeds; switch to intravenous isotonic fluid (e.g., $0.9\%\text{ NaCl} + 5\%\text{ Dextrose}$) at maintenance rate if respiratory rate is $>70\text{/min}$ or severe retractions occur to minimize aspiration risk.
5. Pharmacological Rationale:
   • Bronchodilators (Salbutamol): Infants $<6$ months lack bronchial smooth muscle hypertrophy and mature beta-2 adrenergic receptor density. The primary airway pathology is luminal plugging by cellular debris, submucosal edema, and mucus hypersecretion rather than bronchospasm; randomized trials demonstrate no reduction in hospitalization rates or illness duration.
   • Corticosteroids: Clinical trials (including the large Canadian pediatric emergency research trials) demonstrate that systemic corticosteroids do not reduce hospital admission, reduce duration of mechanical ventilation, or hasten clinical recovery, while exposing infants to potential immunosuppression and metabolic adverse effects.

1. Antimicrobial Adverse Effect Matching:
   • a — iii (Vancomycin — Histamine-mediated flushing / "Red Man Syndrome")
   • b — iv (Clindamycin — Clostridioides difficile-associated pseudomembranous colitis)
   • c — ii (Erythromycin — Infantile hypertrophic pyloric stenosis)
   • d — i (Ciprofloxacin — Tendinopathy and cartilage toxicity)
   • e — vii (Rifampicin — Benign orange-red discoloration of body fluids)
   • f — vi (Chloramphenicol — Gray baby syndrome)
   • g — v (Linezolid — Reversible thrombocytopenia and mitochondrial protein synthesis inhibition)
   • h — viii (Gentamicin — Irreversible cochlear and vestibular ototoxicity)
2. Vancomycin "Red Man Syndrome":
   • Mechanism: Non-immune, rate-dependent degranulation of mast cells and basophils directly triggered by vancomycin, leading to massive systemic histamine release (not an IgE-mediated type I hypersensitivity reaction).
   • Prevention:
     • Prolong infusion time to at least 60 minutes (or a rate $\le 10\text{ mg/min}$ or $\le 500\text{ mg/hr}$).
     • Pre-medicate with an $\text{H}_1$-receptor antagonist (e.g., Diphenhydramine $1\text{ mg/kg}$ IV/oral) prior to the infusion.
3. Fluoroquinolone Cartilage Toxicity:
   • Formation of chelation complexes with magnesium within articular cartilage, causing degradation of chondrocyte extracellular matrix, articular surface blister formation, and tenocyte apoptosis predisposing to tendinopathy/tendon rupture.
4. Linezolid Monitoring and Organelle Toxicity:
   • Monitoring: Weekly complete blood counts (CBC) with differential and platelet count.
   • Target Organelle: Mitochondria (inhibition of mitochondrial ribosomes / protein synthesis due to structural homology between bacterial 50S ribosomal subunits and mitochondrial 39S subunits, causing lactic acidosis, myelosuppression, and peripheral/optic neuropathy).

1. Antidote Matching:
   • a — iv (Deferoxamine — Acute elemental iron poisoning)
   • b — i (N-Acetylcysteine — Acute paracetamol toxicity)
   • c — vii (Pyridoxine — Isoniazid overdose)
   • d — viii (Phytomenadione — Brodifacoum / Superwarfarin rodenticide toxicity)
   • e — vi (Dimercaprol — Severe arsenic, mercury, or lead poisoning)
   • f — ii (Pralidoxime — Organophosphate pesticide toxicity)
   • g — v (Flumazenil — Benzodiazepine overdose)
   • h — iii (Octreotide — Sulfonylurea-induced refractory hypoglycemia)
2. Paracetamol Nomogram and Loading Dose Protocol:
   • Nomogram Cutoff: Reliable only between 4 hours and 24 hours post-acute single ingestion (levels drawn $<4\text{ hours}$ cannot predict hepatotoxicity due to ongoing absorption).
   • Loading Dose: $150\text{ mg/kg}$ IV infused in $5\%\text{ Dextrose}$ ($3\text{ mL/kg}$) over 60 minutes.
3. Elemental Iron Poisoning:
   • Serum Iron Threshold: Peak serum iron level $>500\text{ mcg/dL}$ (or $>350\text{ mcg/dL}$ in the presence of severe metabolic acidosis, shock, or lethargy).
   • Urine Color: "Vin rosé" (red-orange) urine, caused by the urinary excretion of the water-soluble iron-chelate complex (ferrioxamine).
4. Flumazenil Contraindication in Mixed Overdose:
   • Benzodiazepines exert a protective anticonvulsant effect against TCA-induced neurotoxicity. Administering flumazenil abruptly reverses benzodiazepine-mediated $\text{GABA}_\text{A}$ agonism, precipitating intractable seizures, malignant ventricular arrhythmias, and cardiotoxicity secondary to unmasked TCA-mediated sodium channel blockade.

1. WHO Criteria for Antimalarial Treatment Failure:
   • Early Treatment Failure (ETF):
     • Development of danger signs or severe malaria on Day 1, Day 2, or Day 3 in the presence of parasitemia.
     • Parasitemia on Day 2 higher than on Day 0 (irrespective of axillary temperature).
     • Parasitemia on Day 3 with axillary temperature $\ge 37.5^\circ\text{C}$.
     • Parasitemia on Day 3 that is $\ge 25\%$ of the Day 0 parasite count.
   • Late Clinical Failure (LCF):
     • Development of danger signs or severe malaria after Day 3 in the presence of parasitemia, without previously meeting any criteria for ETF.
     • Presence of fever ($\ge 37.5^\circ\text{C}$) and parasitemia on any day between Day 4 and Day 28 (or Day 42 for long-acting artemisinin partner drugs) without previously meeting ETF criteria.
2. Clinical Classification:
   • Early Treatment Failure (ETF).
   • Justification: The child developed danger signs/severe malaria (cerebral malaria with GCS 9) on Day 2 and had a Day 2 parasite density higher than baseline ($110,000/\mu\text{L} > 80,000/\mu\text{L}$).
3. Definition of Premunition:
   • A state of partial, non-sterilizing immunity acquired through chronic, repeated exposures to Plasmodium infection in hyperendemic or holoendemic settings. It allows the host to tolerate low-grade parasitemia asymptomatically without developing severe illness or death. This protective immunity does not eradicate parasitemia and is rapidly lost if the individual leaves the endemic area for an extended period (typically 1–2 years).
4. Rescue Parenteral Dosing Calculation:
   • WHO Artesunate Dose Threshold:
     • Children $<20\text{ kg}$: $3.0\text{ mg/kg/dose}$
     • Children $\ge 20\text{ kg}$ and adults: $2.4\text{ mg/kg/dose}$
       $$ > \begin{aligned} > \text{Patient Weight} &= 20\text{ kg} \quad (\text{Threshold } \ge 20\text{ kg applies}) \\ > \text{Per-dose Artesunate} &= 2.4\text{ mg/kg} \times 20\text{ kg} \\ > &= \mathbf{48\text{ mg/dose}} \quad (\text{IV slow push over 1–2 minutes}) > \end{aligned} > $$
   • Administration Schedule:
     • Dose 1: $48\text{ mg}$ IV stat at $0\text{ hours}$
     • Dose 2: $48\text{ mg}$ IV at $12\text{ hours}$
     • Dose 3: $48\text{ mg}$ IV at $24\text{ hours}$
     • Thereafter, $48\text{ mg}$ IV once every 24 hours until the child can tolerate oral medications (minimum 3 parenteral doses required).
     • Complete therapy with a full 3-day oral course of an alternative, effective ACT (e.g., Artemether-Lumefantrine) once conscious.

1. Antiviral Drug Selection:
   • a. Primary genital HSV: Oral Acyclovir (or oral Valacyclovir).
   • b. Neonatal herpes (CNS/disseminated): Intravenous Acyclovir (high-dose).
   • c. Congenital symptomatic CMV: Oral Valganciclovir (or intravenous Ganciclovir).
   • d. HSV dendritic keratitis: Topical Ganciclovir 0.15% ophthalmic gel (or topical Trifluridine 1% solution).
2. Neonatal HSV Treatment Protocol:
   • Acute phase: Intravenous Acyclovir $60\text{ mg/kg/day}$ divided every 8 hours ($20\text{ mg/kg/dose}$ IV infused over 1 hour every 8 hours) for 21 days for disseminated/CNS disease (14 days if limited to skin, eye, and mouth [SEM] disease).
   • Suppressive phase: Oral Acyclovir $300\text{ mg/m}^2\text{/dose}$ given three times daily for 6 months following completion of intravenous therapy to optimize neurodevelopmental outcomes and prevent cutaneous recurrences.
3. Dose Calculation:
   $$ > \begin{aligned} > \text{Dose per administration} &= 3.2\text{ kg} \times 16\text{ mg/kg/dose} = \mathbf{51.2\text{ mg}} \\ > \text{Volume per administration} &= \frac{51.2\text{ mg}}{50\text{ mg/mL}} = \mathbf{1.024\text{ mL}} \quad (\approx \mathbf{1.0\text{ mL}}) \\ > \text{Total daily dose} &= 51.2\text{ mg} \times 2 = \mathbf{102.4\text{ mg/day}} > \end{aligned} > $$
4. Monitoring and Toxicity:
   • Key toxicities: Severe neutropenia (myelosuppression), thrombocytopenia, and nephrotoxicity (elevated serum creatinine).
   • Withholding threshold: Absolute neutrophil count (ANC) $< 500/\mu\text{L}$ (or severe drop $< 750/\mu\text{L}$ requiring temporary cessation or dose reduction until marrow recovery).

1. Salmonella enterica (serovars such as Salmonella enteritidis or Salmonella typhimurium; non-typhoidal Salmonella species).
2. Streptococcus pyogenes (Group A beta-hemolytic Streptococcus [GAS]).
3. Corynebacterium diphtheriae.
4. Pseudomonas aeruginosa.
5. Bartonella henselae.
6. Neisseria meningitidis (Meningococcus).
7. Helicobacter pylori.
8. Haemophilus influenzae type b (Hib).
9. Clostridium tetani.

1. Microscopic Identification:
   • a. Entamoeba histolytica; Trophozoite stage.
   • b. Erythrophagocytosis (ingested red blood cells within the cytoplasm; definitive feature distinguishing invasive E. histolytica from commensal non-pathogenic Entamoeba dispar).
2. Biomedical Waste Segregation:
   • a. Blood agar plates: Yellow bag (microbiology, biotechnology, and other clinical laboratory waste; pre-treated by autoclaving).
   • b. Used metallic hypodermic needle: White translucent puncture-proof container (PPC) (metallic sharps waste).
   • c. Expired amikacin vial: Yellow bag / cardboard box with yellow marking (expired/discarded cytotoxic and pharmaceutical waste).
   • d. Blood-soaked gauze swabs: Yellow bag (soiled anatomical/cloth waste).
   • e. Contaminated plastic IV set: Red bag (recyclable contaminated plastic waste).
   • f. Incineration ash: Black bag / designated container for disposal in a secured hazardous waste landfill.
3. Antimicrobial Regimen:
   • Tissue amoebicide: Oral Metronidazole $35\text{ to }50\text{ mg/kg/day}$ divided every 8 hours for 7–10 days (or oral Tinidazole $50\text{ mg/kg/day}$ once daily, maximum $2\text{ g/day}$, for 3 days).
   • Followed by luminal amoebicide: Oral Paromomycin $25\text{ to }35\text{ mg/kg/day}$ divided every 8 hours for 7 days (or oral Diloxanide furoate $20\text{ mg/kg/day}$ divided every 8 hours for 10 days).
4. Extraintestinal Complication:
   • Complication: Amoebic liver abscess (ALA).
   • Macroscopic appearance of aspirate: Thick, reddish-brown, odorless, liquefied necrotic material resembling "anchovy paste" (or chocolate sauce).

1. Diagnosis and Localization:
   • Brain abscess localized to the right cerebral hemisphere (frontoparietal or temporoparietal region), with impending uncal (transtentorial) herniation.
2. Pathophysiology in Cyanotic Heart Disease:
   • Loss of pulmonary capillary filtration: Right-to-left intracardiac shunting bypasses the pulmonary reticuloendothelial filter, allowing transient systemic venous bacteremia to seed the cerebral circulation directly.
   • Hypoxemic ischemic tissue damage: Chronic arterial hypoxemia combined with secondary polycythemia (hyperviscosity) causes microvascular sludging and focal cerebral microinfarctions, providing an unoxygenated, devitalized nidus for bacterial colonization.
3. Etiological Agents:
   • Streptococcus species (Streptococcus intermedius, Streptococcus anginosus, viridans group streptococci).
   • Staphylococcus aureus.
   • Anaerobic bacteria (Peptostreptococcus species, Bacteroides fragilis, Fusobacterium species).
4. Contraindication to Lumbar Puncture:
   • Space-occupying intracranial mass with significant perilesional vasogenic edema and midline shift carries a high risk of catastrophic brainstem herniation (coning). Additionally, CSF analysis has low diagnostic sensitivity for intact, unruptured brain abscesses.
5. Empirical Intravenous Antibiotic Therapy:
   • Ceftriaxone: $100\text{ mg/kg/day}$ IV divided every 12 hours (maximum $4\text{ g/day}$) OR Cefotaxime: $200\text{ mg/kg/day}$ IV divided every 6 hours.
   • PLUS Metronidazole: $30\text{ mg/kg/day}$ IV divided every 8 hours (for anaerobic coverage).
   • PLUS Vancomycin: $60\text{ mg/kg/day}$ IV divided every 6 hours (to cover MRSA; target trough 15–20 mcg/mL).
   • Total duration: 4 to 6 weeks of intravenous therapy (minimum 6–8 weeks if managed non-operatively without aspiration).

1. Diagnosis & WHO Defining Criteria:
   • Diagnosis: Cerebral malaria (Severe Plasmodium falciparum malaria).
   • WHO Criteria:
     • Presence of asexual forms of Plasmodium falciparum on blood smear or positive rapid diagnostic test.
     • Unarousable coma persisting for >1 hour after termination of a seizure or correction of hypoglycemia (Blantyre Coma Score $\le 2$ in young children or Glasgow Coma Scale score $< 11$ in older children/adults).
     • Exclusion of other encephalopathies or causes of altered sensorium (e.g., bacterial/viral meningoencephalitis, severe hypoglycemia).
2. Antimalarial Regimen (WHO / National Guidelines):
   • First-line Agent: Intravenous (IV) Artesunate.
   • Initial Dosing Schedule:
     • Dose: $2.4\text{ mg/kg/dose}$ IV (for children weighing $\ge 20\text{ kg}$; if $<20\text{ kg}$, recommended dose is $3.0\text{ mg/kg/dose}$).
     • Schedule: Given at $0\text{ hours}$, $12\text{ hours}$, and $24\text{ hours}$, then once daily ($2.4\text{ mg/kg}$ every 24 hours) for a minimum of 24 hours (at least 3 parenteral doses) until the child can swallow oral medications.
     • Calculation for this 25 kg patient: $25\text{ kg} \times 2.4\text{ mg/kg} = \mathbf{60\text{ mg IV per dose}}$.
   • Step-down Oral Regimen:
     • Once conscious and tolerating orally, complete a full 3-day course of Artemisinin-based Combination Therapy (ACT): Artemether-Lumefantrine ($20/120\text{ mg}$ fixed-dose combination: 2 tablets twice daily for 3 days) or Artesunate + Sulfadoxine-Pyrimethamine (as per local national drug policy).
3. Immediate Supportive Interventions (First 2 Hours):
   • Hypoglycemia Correction: Administer $2\text{ mL/kg}$ of $10\%$ Dextrose as an IV bolus ($50\text{ mL}$ for 25 kg) followed by continuous dextrose-containing maintenance fluids; monitor blood glucose every 4 hours.
   • Airway & Seizure Management: Place in recovery position, maintain clear airway, administer high-flow oxygen; treat acute seizures promptly with IV Midazolam ($0.1–0.2\text{ mg/kg}$) or IV Lorazepam ($0.1\text{ mg/kg}$).
   • Fluid Balance & Restriction: Maintain euvolemia; avoid hyperhydration/fluid boluses due to high risk of non-cardiogenic pulmonary edema and brain edema (infuse maintenance fluids at $2/3\text{rd}$ to full maintenance rate using isotonic crystalloids with dextrose).
   • Fever & Diagnostic Lumbar Puncture: Administer paracetamol suppository/IV ($15\text{ mg/kg}$) to control hyperpyrexia; perform diagnostic lumbar puncture once elevated intracranial pressure and active seizures are controlled to rule out bacterial/viral co-infection.
4. Pathophysiology of Microvascular Sequestration:
   • Parasite-derived protein Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP-1) is expressed as "knobs" on the surface of infected red blood cells (iRBCs).
   • PfEMP-1 binds host vascular endothelial receptors, primarily CD36, Intercellular Adhesion Molecule 1 (ICAM-1), and Endothelial Protein C Receptor (EPCR).
   • This cytoadherence causes sequestration of mature trophozoites and schizonts in cerebral microcapillaries, sparing them from splenic clearance.
   • Rosetting (binding of iRBCs to uninfected RBCs) and autoagglutination cause mechanical microvascular occlusion, tissue hypoxia, impaired endothelial barrier function, localized nitric oxide depletion, and localized cerebral edema.

flowchart TD
    A[Mature P. falciparum inside RBCs] --> B[Expression of PfEMP-1 'knobs']
    B --> C[Cytoadherence to endothelial EPCR, ICAM-1, CD36]
    B --> D[Rosetting with uninfected erythrocytes]
    C & D --> E[Microvascular Sequestration & Capillary Occlusion]
    E --> F[Reduced Cerebral Perfusion & Localized Tissue Hypoxia]
    E --> G[Blood-Brain Barrier Disruption & Perivascular Edema]
    F & G --> H[Coma, Intracranial Hypertension, & Epileptogenesis]

1. Matching of Pathogens with Characteristic Features:
   • A $\rightarrow$ 2: Congenital Cytomegalovirus $\rightarrow$ Sensorineural hearing loss, periventricular calcifications, and microcephaly.
   • B $\rightarrow$ 5: Congenital Toxoplasmosis $\rightarrow$ Hydrocephalus, diffuse parenchymal intracerebral calcifications, and chorioretinitis (Sabin Classic Triad).
   • C $\rightarrow$ 3: Congenital Rubella Syndrome $\rightarrow$ Cataracts, patent ductus arteriosus (PDA), and "salt-and-pepper" retinopathy (Gregg Triad).
   • D $\rightarrow$ 1: Congenital Varicella Syndrome $\rightarrow$ Cigarette-paper scar/cicatricial cutaneous lesions with hypoplastic limb and Horner syndrome.
   • E $\rightarrow$ 4: Congenital Zika Virus Syndrome $\rightarrow$ Severe microcephaly with craniofacial disproportion, redundant scalp skin folds, and fetal brain disruption sequence.
2. Diagnostic Confirmation for Congenital CMV:
   • Modality & Sample: Detection of CMV DNA by Polymerase Chain Reaction (PCR) or viral culture in urine or saliva collected within the first 21 days of life (testing after 3 weeks cannot distinguish congenital from postnatally acquired CMV).
3. Pharmacotherapy for Symptomatic Congenital CMV:
   • First-line Drug: Oral Valganciclovir.
   • Dose & Route: $16\text{ mg/kg/dose}$ orally twice daily (every 12 hours).
   • Alternative (if oral not tolerated): Intravenous Ganciclovir at $6\text{ mg/kg/dose}$ IV every 12 hours.
   • Duration: Total duration of 6 months.
   • Monitoring: Complete blood count with absolute neutrophil count (ANC) at baseline and weeks 2, 4, and monthly thereafter (risk of severe neutropenia).
4. Ophthalmology & Calcification Characteristics:
   • Ocular Finding in Toxoplasmosis: Focal necrotizing chorioretinitis (classically bilateral, involving the macula).
   • Calcification Pattern Distinction:
     • Toxoplasmosis: Diffuse, scattered parenchymal intracranial calcifications distributed randomly throughout cortex, basal ganglia, and periventricular zones.
     • Cytomegalovirus: Predominantly periventricular calcifications bordering the subependymal germinal matrix lining the lateral ventricles.

1. Definitive Diagnosis:
   • Early Congenital Syphilis (Treponema pallidum infection).
2. Radiological Signs on Long-Bone Radiography:
   • Wimberger sign: Symmetrical erosions/demineralization of the medial aspect of the upper proximal tibial metaphysis.
   • Osteochondritis / Metaphysitis: Transverse alternating radiolucent and sclerotic metaphyseal bands ("sawtooth" or "celery-stalk" appearance).
   • Periostitis / Diaphysitis: Symmetrical layered subperiosteal new bone formation along the diaphyses of long tubular bones.
   • Parrot pseudoparalysis: Functional paralysis secondary to severe painful metaphysitis/periostitis.
3. Serological Diagnostic Criteria:
   • Reactive neonatal non-treponemal titer (VDRL or RPR) that is four-fold higher (i.e., a two-dilution difference, e.g., 1:16 vs. 1:4) than the maternal non-treponemal titer at the time of delivery; OR
   • Identification of Treponema pallidum by dark-field microscopy, fluorescent antibody test, or PCR from nasal discharge, placenta, umbilical cord, or skin lesion exudate; OR
   • Persistently reactive non-treponemal test beyond 6–12 months of age or reactive treponemal test (FTA-ABS / TP-PA) persisting beyond 15–18 months of age (confirming neonatal antibody synthesis rather than transplacental maternal IgG).
4. Definitive Antimicrobial Regimen:
   • Aqueous Crystalline Penicillin G:
     • Dose: $50,000\text{ units/kg/dose}$ IV.
     • Frequency: Every 12 hours during the first 7 days of life, and every 8 hours thereafter (days 8–10).
     • Total Duration: 10 continuous days (if even 1 day of therapy is missed, the entire 10-day course must be restarted).
   • Alternative: Procaine Penicillin G $50,000\text{ units/kg/dose}$ IM once daily for 10 days.
5. Late Clinical Sequelae (Manifestations >2 Years):
   • Hutchinson triad: Hutchinson teeth (peg-shaped, notched upper central incisors), interstitial keratitis, and eighth-nerve sensorineural deafness.
   • Skeletal deformities: "Saber shins" (anterior bowing of tibia), Clutton joints (painless symmetrical hydrarthrosis, usually of knees), frontal bossing of Fournier/Parrot, saddle nose deformity.
   • Cutaneous / Mucosal signs: Rhagades (linear perioral and perianal radiating scars), mulberry molars (first permanent molars with multiple poorly developed cusps).

1. Diagnosis & Primary Etiology:
   • Diagnosis: Acute Laryngotracheobronchitis (Viral Croup).
   • Primary Pathogen: Human Parainfluenza Virus type 1 (HPIV-1) (followed by HPIV-2, HPIV-3, RSV, and Influenza viruses).
2. Radiological Sign & Anatomical Basis:
   • Sign: "Steeple sign" (or "pencil-tip" sign / inverted "V" sign) on anteroposterior (AP) neck projection.
   • Anatomical Basis: Symmetrical subglottic airway narrowing caused by inflammatory mucosal edema and cellular infiltration of the lax submucosa of the conus elasticus, leading to loss of the normal horizontal shoulders of the subglottic trachea.
3. Westley Croup Score Calculation & Severity:
   • Scoring Components:
     • Inspiratory Stridor: Audible at rest $\rightarrow \mathbf{2\text{ points}}$
     • Retractions: Moderate $\rightarrow \mathbf{2\text{ points}}$
     • Air Entry: Normal to mild decrease $\rightarrow \mathbf{0–1\text{ point}}$
     • Cyanosis: None $\rightarrow \mathbf{0\text{ points}}$
     • Level of Consciousness: Normal/Alert $\rightarrow \mathbf{0\text{ points}}$
   • Total Score: $4–5\text{ points}$.
   • Severity Classification: Moderate Croup (Mild: $\le 2$; Moderate: $3–5$; Severe: $6–11$; Impending Respiratory Failure: $\ge 12$).
4. Definitive Pharmacotherapy & Discharge Criteria:
   • Systemic Corticosteroid (Cornerstone):
     • Dexamethasone: $0.15\text{ to }0.6\text{ mg/kg}$ (maximum $16\text{ mg}$) as a single dose orally or intramuscularly/intravenously.
     • Alternative: Nebulized Budesonide $2\text{ mg}$ single dose (if vomiting or severe distress).
   • Nebulized Epinephrine (for Moderate to Severe cases with rest stridor):
     • Racemic Epinephrine $2.25\%$ ($0.05\text{ mL/kg/dose}$, maximum $0.5\text{ mL}$) OR L-Epinephrine $1:1000$ ($0.5\text{ mL/kg}$, max $5\text{ mL}$) nebulized over 10–15 minutes with oxygen.
   • Discharge Criteria:
     • Minimum observation of 3–4 hours after nebulized epinephrine (to monitor for rebound stridor).
     • Absence of stridor at rest.
     • Normal oxygenation ($\text{SpO}_2 \ge 94\%$ on room air) and no retractions.
     • Normal sensorium, ability to tolerate oral fluids, and reliable caregivers with access to emergency return.

1. Matching of Tests to Pathogens:
   • A $\rightarrow$ 3: Weil–Felix test $\rightarrow$ Scrub typhus / Rickettsial spotted fevers.
   • B $\rightarrow$ 1: Microscopic Agglutination Test (MAT) $\rightarrow$ Leptospira interrogans.
   • C $\rightarrow$ 5: Paul–Bunnell test / Heterophile antibody test $\rightarrow$ Epstein–Barr Virus (Infectious Mononucleosis).
   • D $\rightarrow$ 4: Quantitative Buffy Coat (QBC) technique $\rightarrow$ Plasmodium species.
   • E $\rightarrow$ 2: India ink negative staining of CSF $\rightarrow$ Cryptococcus neoformans.
   • F $\rightarrow$ 6: Tzanck smear showing multinucleated giant cells $\rightarrow$ Herpes Simplex Virus / Varicella Zoster Virus.
2. Weil–Felix Test Principle & Limitations:
   • Principle: A heterophile agglutination reaction based on cross-reactivity (molecular mimicry) between shared somatic carbohydrate antigens of certain non-motile Proteus strains (Proteus vulgaris OX-19, OX-2, and Proteus mirabilis OX-K) and specific antigens of rickettsial organisms (Rickettsia prowazekii, R. rickettsii, and Orientia tsutsugamushi).
   • Limitations:
     • Low Sensitivity: Negative during the first 7–10 days of illness; false-negative results are common.
     • Low Specificity: Cross-reacts with urinary tract or systemic infections caused by Proteus species, Borrelia, and severe hepatic disorders.
3. Gold-Standard for Leptospirosis & Diagnostic Threshold:
   • Gold Standard: Microscopic Agglutination Test (MAT) using live leptospiral serovars.
   • Diagnostic Cutoff:
     • A four-fold or greater rise in MAT titer between paired acute and convalescent serum samples; OR
     • A single reciprocal titer of $\ge 1:400$ (or $\ge 1:800$ in endemic regions) in a patient with a compatible acute clinical presentation.
4. India Ink Mechanism & High-Sensitivity Alternative:
   • Structural Component: The thick, extracellular glucuronoxylomannan polysaccharide capsule, which excludes the colloidal carbon particles of India ink, creating a clear halo around the budding yeast cells under light microscopy.
   • Higher Sensitivity Alternative: Cryptococcal Antigen (CrAg) Lateral Flow Assay (LFA) or latex agglutination test in CSF or serum ($>98\%$ sensitivity).

1. Morphological Description & Clinical Diagnosis:
   • Lesion Description: Well-demarcated, full-thickness dermal "punched-out" ulceration covered with an adherent, thick, hard, dark brown-to-black necrotic crust, surrounded by an elevated, indurated, violaceous or erythematous border.
   • Definitive Diagnosis: Ecthyma (deep / ulcerative impetigo).
2. Causative Pathogens:
   • Primary Organism: Streptococcus pyogenes (Group A Beta-Hemolytic Streptococcus, GABS).
   • Secondary / Co-infecting Organism: Staphylococcus aureus (including Methicillin-Sensitive S. aureus [MSSA] and Community-Acquired Methicillin-Resistant S. aureus [CA-MRSA]).
3. Associated Complications:
   • Group A Streptococcus:
     • Post-Streptococcal Glomerulonephritis (PSGN) (nephritogenic strains; Note: Acute Rheumatic Fever does not follow cutaneous streptococcal infections).
     • Invasive streptococcal disease / Streptococcal Toxic Shock Syndrome (STSS) or cellulitis/lymphangitis.
   • Staphylococcus aureus:
     • Staphylococcal Scalded Skin Syndrome (SSSS) / bullous impetigo spread.
     • Invasive deep-tissue or metastatic hematogenous seeding (suppurative osteomyelitis, septic arthritis, staphylococcal toxic shock syndrome).
4. Definitive Management Plan (Child Weight: 22 kg):
   • Local Wound Hygiene & Debridement:
     • Warm compresses soaked in normal saline or dilute chlorhexidine/potassium permanganate (1:10,000) applied for 15–20 minutes 3 times daily to soften and gently remove adherent crusts without aggressive scrubbing.
     • Application of topical mupirocin 2% ointment or fusidic acid 2% cream 3 times daily to de-crusted lesions.
   • Systemic Antimicrobial Therapy (First-Line Empirical):
     • Oral Amoxicillin-Clavulanate: $45 \text{ mg/kg/day}$ (amoxicillin component) orally divided every 12 hours for 7–10 days:
       $$ > \begin{aligned} > \text{Total Daily Dose} &= 22 \text{ kg} \times 45 \text{ mg/kg/day} = 990 \text{ mg/day} \\ > \text{Per-Dose Amount} &= \frac{990 \text{ mg}}{2} \approx \mathbf{500 \text{ mg orally twice daily for 7--10 days}} > \end{aligned} > $$
     • Alternative (if penicillin allergic, non-anaphylactic): Cephalexin $50 \text{ mg/kg/day}$ divided every 6 to 8 hours ($275 \text{ mg}$ orally 4 times daily) for 7–10 days.
     • Alternative (suspected/confirmed CA-MRSA or severe hypersensitivity): Clindamycin $30 \text{ mg/kg/day}$ divided every 8 hours ($220 \text{ mg}$ orally 3 times daily) for 7–10 days, or Trimethoprim-Sulfamethoxazole ($8 \text{ mg/kg/day}$ TMP component divided every 12 hours).

graph TD
    A[Minor Cutaneous Trauma / Insect Bite] --> B[Epidermal Breach & Bacterial Inoculation: GABS ± S. aureus]
    B --> C[Initial Vesicle or Pustule Formation]
    C --> D[Extension Across Dermal-Epidermal Junction into Deep Dermis]
    D --> E[Tissue Necrosis & Full-Thickness Punched-Out Ulcer]
    E --> F[Hard Adherent Necrotic Crust with Violaceous Indurated Rim: Ecthyma]
    F --> G[Healing by Granulation: Leaves Permanent Depressed Scarring]

Unlike impetigo contagiosa (which is superficial, intraepidermal, subcorneal, and heals without scar formation), ecthyma penetrates deeply into the dermis. Consequently, ecthyma typically heals with permanent scarring and post-inflammatory pigmentary alteration.

1. True/False Evaluation:
   • a. False: Only ~10% of individuals colonized with Entamoeba histolytica develop invasive symptomatic colitis; ~90% remain asymptomatic cyst passers.
   • b. False: Cysts represent the non-motile, infectious, non-invasive carrier stage. Acute invasive amebic colitis is mediated exclusively by hematophagous trophozoites invading the colonic mucosa.
   • c. False: E. histolytica, E. dispar, and E. moshkovskii are morphologically indistinguishable by conventional light microscopy in both cyst and trophozoite stages.
   • d. True: Hematophagy (trophozoites with phagocytosed red blood cells) is pathognomonic for invasive E. histolytica and is not exhibited by E. dispar.
2. Diagnostic Superiority of Antigen Detection & PCR:
   • Fecal Antigen ELISA: Specifically targets the Gal/GalNAc lectin of E. histolytica; provides sensitivity >95% and differentiates pathogenic E. histolytica from non-pathogenic E. dispar directly from stool within hours.
   • Real-Time Stool PCR: Represents the gold standard; amplifies specific 18S ribosomal RNA or episomal DNA targets, offering near 100% sensitivity and specificity, unaffected by morphologic mimicry or cyst excretion variability.
3. Histopathology & Abscess Pathogenesis:
   • Intestinal Histology: "Flask-shaped" ulceration—trophozoites adhere via Gal/GalNAc lectin, lyse the surface epithelial barrier via amoebapores and cysteine proteinases, penetrate vertically down to the lamina propria, and expand horizontally beneath intact mucosa within the submucosa.
   • Extraintestinal Spread (Amebic Liver Abscess): Trophozoites breach deep colonic submucosal venules, enter the mesenteric-portal venous circulation, and embolize to the liver (predominantly the posterior superior segment of the right hepatic lobe), producing focal enzymatic liquefactive necrosis containing sterile brownish "anchovy-paste" fluid.
4. Comprehensive Two-Stage Therapeutic Regimen (Child Weight: 20 kg):
   • Stage 1: Tissue Amebicide (Eliminate Invasive Trophozoites):
     • Metronidazole: $35\text{--}50 \text{ mg/kg/day}$ orally divided every 8 hours for 7–10 days:
       $$ > \begin{aligned} > \text{Total Daily Dose} &= 20 \text{ kg} \times 40 \text{ mg/kg/day} = 800 \text{ mg/day} \\ > \text{Per-Dose Amount} &= \frac{800 \text{ mg}}{3} \approx \mathbf{250\text{--}270 \text{ mg orally every 8 hours for 7--10 days}} > \end{aligned} > $$
     • Alternative: Tinidazole $50 \text{ mg/kg/day}$ (max $2 \text{ g}$) orally once daily with food for 3 days ($1000 \text{ mg}$ once daily).
   • Stage 2: Luminal Amebicide (Eradicate Residual Intraluminal Cysts):
     • Mandatory following tissue amebicide to prevent relapses and interrupt public transmission:
     • Paromomycin: $25\text{--}35 \text{ mg/kg/day}$ orally divided every 8 hours for 7 days:
       $$ > \begin{aligned} > \text{Total Daily Dose} &= 20 \text{ kg} \times 30 \text{ mg/kg/day} = 600 \text{ mg/day} \\ > \text{Per-Dose Amount} &= \mathbf{200 \text{ mg orally every 8 hours for 7 days}} > \end{aligned} > $$
     • Alternative: Diloxanide furoate $20 \text{ mg/kg/day}$ orally divided every 8 hours for 10 days ($130\text{--}140 \text{ mg}$ 3 times daily).

1. Diagnosis & Causative Agent:
   • Clinical Diagnosis: Erythema Infectiosum (Fifth Disease / "Slapped-Cheek" Disease).
   • Causative Agent: Human Parvovirus B19 (Family Parvoviridae; non-enveloped, single-stranded linear DNA virus).
2. Three Stages of the Exanthem:
   • Stage 1 (Facial Erythema): Sudden appearance of fiery-red, confluent maculopapular erythema over both cheeks ("slapped-cheek" appearance) with prominent circumoral pallor; lasts 2–4 days.
   • Stage 2 (Truncal & Extremity Spread): Evanescent erythematous macular rash spreads to the extensor surfaces of the extremities and trunk 1–4 days later; central clearing creates a distinctive lace-like, reticulated ("garland-like") pattern.
   • Stage 3 (Evanescence & Recrudescence): The rash fades over 1–3 weeks but characteristically fluctuates or recurs in response to environmental triggers (sunlight exposure, ambient heat, exercise, friction, or emotional stress).
3. Life-Threatening / Severe Complications:
   • Transient Aplastic Crisis (TAC): In children with chronic underlying hemolytic anemias (e.g., sickle cell disease, hereditary spherocytosis, beta-thalassemia major, pyruvate kinase deficiency), characterized by abrupt cessation of erythropoiesis with absolute reticulocytopenia (<0.1%).
   • Non-Immune Hydrops Fetalis / Intrauterine Fetal Demise: When contracted during maternal pregnancy (especially before 20 weeks gestation), secondary to profound fetal anemia, high-output congestive heart failure, and myocarditis.
   • Chronic Pure Red Cell Aplasia (PRCA): In immunocompromised hosts (e.g., severe combined immunodeficiency, post-chemotherapy, solid-organ/hematopoietic transplant recipients, HIV/AIDS) due to inability to mount neutralizing anti-B19 antibodies.
4. Receptor & Laboratory Confirmation:
   • Cellular Receptor: Erythrocyte P antigen (globoside / glycosphingolipid), present on erythroid progenitor cells, megakaryocytes, and endothelial cells.
   • Diagnostic Modality:
     • a. Immunocompetent Child: Serum Parvovirus B19 IgM enzyme-linked immunosorbent assay (ELISA) (detectable within 7–10 days post-exposure and remains positive for 2–3 months).
     • b. Immunocompromised Host: Quantitative Serum Parvovirus B19 DNA by Real-Time Polymerase Chain Reaction (RT-PCR) (serology is falsely negative due to defective humoral antibody responses).

graph LR
    A[Parvovirus B19 Inhalation / Droplet Transmission] --> B[Viremia: Day 7-14]
    B --> C[Invasion via Erythrocyte P Antigen Globoside]
    C --> D[Lysis of Erythroid Progenitor Cells CFU-E / BFU-E]
    D --> E[Transient Erythropoietic Arrest 7-10 Days]
    B --> F[Immune Complex Deposition: Day 16-28]
    F --> G[Slapped Cheek Rash & Reticular Exanthem]
    F --> H[Post-Infectious Arthropathy / Arthritis]

Infectivity Note: By the time the classic "slapped-cheek" exanthem appears, the viremic phase has terminated and the child is no longer infectious. Routine exclusion from school or daycare at the rash stage is clinically unnecessary.

1. Rash Identification & Underlying Disease:
   • Cutaneous Rash: Erythema Marginatum (Erythema marginatum rheumaticum).
   • Underlying Systemic Condition: Acute Rheumatic Fever (ARF).
2. Four Classic Morphological Hallmarks:
   • Evanescent & Migratory: Lesions appear, change shape within hours, disappear, and re-emerge rapidly elsewhere.
   • Polycyclic / Serpiginous Architecture: Starts as pinkish-red macules that expand centrifugally with central clearing, leaving a sharp, raised, wavy, or snake-like outer border.
   • Non-Pruritic & Non-Indurated: Causes no itching, tenderness, or epidermal desquamation; blanches completely upon diascopy.
   • Truncal & Proximal Distribution: Located primarily on the trunk, abdomen, and inner aspects of proximal extremities; strictly spares the face.
3. Revised Jones Criteria (2015) Categorization:
   • Classification: Major Manifestation (for both low-risk and moderate/high-risk populations).
   • Remaining Four Major Criteria:
     • Carditis (clinical and/or subclinical echocardiographic valvulitis).
     • Polyarthritis (or monoarthritis/polyarthralgia in moderate-to-high risk populations).
     • Sydenham Chorea (St. Vitus dance).
     • Subcutaneous nodules (firm, painless nodules over bony prominences/extensor tendons).
4. Secondary Antimicrobial Prophylaxis Regimen (Child Weight: 28 kg):
   • Drug of Choice: Benzathine Penicillin G (BPG).
   • Dose & Route: $1,200,000\text{ Units}$ (1.2 million units) deep intramuscularly:
     $$ > \text{Dose Threshold} = \begin{cases} > 600,000\text{ Units IM} & \text{if weight } \le 27\text{ kg} \\ > \mathbf{1,200,000\text{ Units IM}} & \mathbf{\text{if weight } > 27\text{ kg (Patient is 28 kg)}} > \end{cases} > $$
   • Frequency: Every 3 to 4 weeks (every 3 weeks is preferred in high-risk endemic settings).
   • Alternative (in severe penicillin allergy): Oral Erythromycin $250 \text{ mg}$ orally twice daily, or Azithromycin $5 \text{ mg/kg/day}$ (max $250 \text{ mg}$) once daily.
   • Total Recommended Duration (ARF with Carditis and Persistent Valvular Disease):
     • For 10 years from the last attack or until 40 years of age (whichever is longer); sometimes lifelong if severe chronic rheumatic heart disease or post-valve surgery. (Note: If carditis had resolved without residual valvular damage, minimum 10 years or until 21 years of age).

1. Parasite Identification & Morphology:
   • Organism & Stage: Giardia duodenalis (also known as Giardia lamblia or Giardia intestinalis), Trophozoite stage.
   • Characteristic Features:
     • Pyriform (pear-shaped or teardrop-shaped), dorsoventrally flattened with bilateral symmetry.
     • Possesses two oval symmetrical nuclei with central karyosomes ("face-like" or "spectacle-like" appearance).
     • Ventral concavity containing a large bilobed adhesive suction disc.
     • Four pairs of flagella (anterior, posterior, ventral, and caudal) producing a classic "falling-leaf" motility in fresh wet mounts.
2. Diagnostic Sampling & Non-Microscopic Assays:
   • Sampling Strategy: Trophozoites and cysts are excreted intermittently. A single stool examination has only 50–70% sensitivity. Examining three separate stool specimens collected on alternate days increases the diagnostic sensitivity to >90%.
   • Non-Microscopic Stool Assays:
     • Stool Fecal Antigen Detection (Enzyme Immunoassay [EIA] / Rapid Immuno-chromatographic assay targeting Giardia-specific antigen 65 [GSA-65]).
     • Multiplex Polymerase Chain Reaction (PCR) stool panel.
3. Pathophysiology of Malabsorption vs. Invasive Enteritis:
   • Giardia duodenalis: Non-invasive flagellate that attaches via its ventral adhesive disc to the brush border of duodenal and upper jejunal enterocytes. Causes diffuse blunting/atrophy of microvilli, enterocyte apoptosis, inhibition of brush-border disaccharidases (lactase deficiency), breakdown of tight-junctional zonula occludens-1 (ZO-1), and deconjugation of bile salts, leading to osmotic diarrhea and steatorrhea without tissue invasion or hematochezia.
   • Invasive Enteritis (Shigella): Directly invades colonic enterocytes via type III secretion systems, causes intracellular replication, cell-to-cell spread, profound mucosal ulceration, severe acute neutrophilic inflammation, and microabscesses, leading to bloody/mucoid dysentery.
4. Pharmacological Prescriptions (Child Weight: 14 kg):
   • a. First-Line Metronidazole:
     • Dose: $15\text{--}30 \text{ mg/kg/day}$ orally divided every 8 hours for 5–7 days:
       $$ > \begin{aligned} > \text{Total Daily Dose} &= 14 \text{ kg} \times 15 \text{ mg/kg/day} = 210 \text{ mg/day} \\ > \text{Per-Dose Amount} &= \frac{210 \text{ mg}}{3} = \mathbf{70 \text{ mg orally every 8 hours (TID) for 5--7 days}} > \end{aligned} > $$
   • b. Alternative Short-Course Therapy:
     • Tinidazole (Single-Dose): $50 \text{ mg/kg}$ orally as a single dose taken with food (max $2 \text{ g}$):
       $$ > \text{Single Dose} = 14 \text{ kg} \times 50 \text{ mg/kg} = \mathbf{700 \text{ mg orally as a single stat dose}} > $$
     • Nitazoxanide (Age 1–3 years: 100 mg BID; Age 4–11 years: 200 mg BID): For this 4-year-old child: $\mathbf{200 \text{ mg orally twice daily with food for 3 days}}$.

1. Clinical Diagnosis & Etiology:
   • Diagnosis: Hand, Foot, and Mouth Disease (HFMD).
   • Etiologic Agents: Enterovirus genus (Picornaviridae family), primarily Coxsackievirus A16 (CVA16) and Enterovirus A71 (EV-A71). Less commonly, atypical and widespread exanthems are caused by Coxsackievirus A6 (CVA6) and Coxsackievirus A10 (CVA10).
2. Transmission & Incubation:
   • Routes of Transmission:
     • Fecal-oral route (shedding persists in stool for up to 4–8 weeks).
     • Direct contact with infectious droplets or respiratory secretions.
     • Direct contact with fluid from cutaneous vesicles.
     • Contact with contaminated fomites.
   • Incubation Period: 3 to 5 days (range: 2–7 days).
3. Red Flags for Severe Disease (specifically EV-A71 neuro-cardiopulmonary storm):
   • Persistent high-grade fever $\ge 38.5^\circ\text{C}$ lasting $>72\text{ hours}$.
   • Neurological symptoms: Prominent myoclonic jerks (especially during sleep), lethargy, ataxia, tremor, cranial nerve palsies, or acute flaccid paralysis.
   • Autonomic nervous system dysregulation: Resting tachycardia out of proportion to fever, diaphoresis, cold clammy peripheries, mottled skin, and transient hypertension.
   • Cardiopulmonary collapse: Tachypnea, grunting, frothy pink or blood-tinged sputum, pulmonary edema, and sudden refractory hypotension.
4. Delayed Dermatologic Sequel & Symptomatic Management:
   • Delayed Sequel: Onychomadesis (complete painless shedding of nail plates beginning at the proximal fold) or Beau lines, occurring 4 to 8 weeks post-infection (particularly common after CVA6 and EV-A71).
   • Supportive Pharmacotherapy:
     • Oral Paracetamol: $15\text{ mg/kg/dose}$ PO every 4–6 hours as needed (maximum $60\text{ mg/kg/day}$).
     • Oral Ibuprofen: $10\text{ mg/kg/dose}$ PO every 6–8 hours as needed (maximum $40\text{ mg/kg/day}$; avoid in dehydration).
     • Fluid rehydration: Cold, non-acidic, bland fluids to prevent dehydration; topical oral mucosal barrier gels or soothing rinses (avoid topical lidocaine in small children due to seizure/toxicity risk from systemic absorption).

1. Immediate Wound Care & Baseline Serology:
   • Local Decontamination:
     • Immediately wash the wound gently with soap and copious running water for several minutes.
     • Do not aggressively scrub, squeeze, or apply caustic agents (e.g., bleach, iodine, or alcohol into deep tissue layers), as this disrupts tissue integrity and may enhance viral inoculate entry.
   • Baseline Serologic Workup:
     • Child: Baseline Hepatitis B surface antigen (HBsAg), antibody to Hepatitis B surface antigen (anti-HBs), and antibody to Hepatitis B core antigen (total anti-HBc). Screen also for HIV-1/2 antibodies and anti-HCV antibodies.
2. Post-Exposure Prophylaxis (PEP) Protocol:
   • Combination Therapy: Administer both Hepatitis B Immune Globulin (HBIG) and the first dose of the Hepatitis B vaccine series concurrently.
   • Therapeutic Window:
     • Must be initiated as soon as possible, ideally within 24 hours of exposure.
     • Maximum therapeutic window for HBIG efficacy after percutaneous exposure is 7 days (up to 14 days for sexual assault or perinatal exposure).
3. Mathematical Calculation & Administration:
   $$ > \begin{aligned} > \text{HBIG Dose Volume} &= \text{Body Weight (kg)} \times 0.06\text{ mL/kg} \\ > &= 18\text{ kg} \times 0.06\text{ mL/kg} \\ > &= \mathbf{1.08\text{ mL}} > \end{aligned} > $$
   • Administration:
     • Administer $1.08\text{ mL}$ HBIG via intramuscular (IM) injection.
     • Administer age-appropriate Hepatitis B vaccine ($10\ \mu\text{g} / 0.5\text{ mL}$) IM simultaneously.
     • Inject at separate anatomical sites using separate syringes (e.g., HBIG into the right anterolateral thigh/deltoid and the vaccine into the left anterolateral thigh/deltoid).
     • Complete the full 3-dose vaccine series at months 0, 1, and 6. Check post-vaccination serology (anti-HBs and HBsAg) 1–2 months after the final dose (months 9–12).
4. Prophylaxis Schedule in Pediatric Hemodialysis / ESRD:
   • Higher Antigen Dose: Administer double the standard pediatric dose (e.g., $20\ \mu\text{g}$ or specialized $40\ \mu\text{g}$ formulation) due to uremia-induced hyporesponsiveness.
   • Accelerated / Multi-dose Schedule: A 4-dose primary series administered at 0, 1, 2, and 6 months.
   • Post-vaccination Monitoring & Boosters:
     • Test anti-HBs titers annually.
     • If anti-HBs drops below $10\text{ mIU/mL}$, administer an immediate booster dose.

1. Diagnosis & Etiology:
   • Diagnosis: Herpes Simplex Encephalitis (HSE).
   • Pathogen: Herpes Simplex Virus Type 1 (HSV-1) ($>90\%$ of pediatric cases beyond the neonatal period; HSV-2 is predominantly seen in neonates).
2. Diagnostic Evaluation:
   • CSF Findings:
     • Lymphocytic pleocytosis (typically 10–500 leukocytes/$\mu\text{L}$).
     • Elevated protein concentration ($60\text{–}150\text{ mg/dL}$).
     • Normal to mildly reduced glucose ratio ($>50\%$ of blood glucose).
     • Presence of red blood cells (RBCs) and xanthochromia reflecting necrotizing hemorrhagic viral encephalitis.
   • Confirmatory Gold Standard: CSF HSV-1/2 DNA Polymerase Chain Reaction (PCR) (sensitivity and specificity $>95\%$).
   • EEG Signature: Periodic Lateralized Epileptiform Discharges (PLEDs) or frontotemporal periodic sharp and slow wave complexes occurring at regular intervals (1 to 2 Hz).
3. First-Line Pharmacotherapy:
   • Drug: Intravenous Acyclovir.
   • Dosage:
     • Children (3 months to 12 years): $500\text{ mg/m}^2/\text{dose}$ IV every 8 hours OR $20\text{ mg/kg/dose}$ IV every 8 hours.
     • Children $>12$ years: $10\text{–}15\text{ mg/kg/dose}$ IV every 8 hours.
   • Infusion Duration: Infuse slowly over at least 1 hour (ensuring liberal pre- and post-hydration to prevent obstructive crystalline nephropathy).
   • Duration of Therapy: 14 to 21 days (minimum 21 days in neonates or immunocompromised patients).
4. End-of-Treatment Protocol & Rationale:
   • Mandatory Investigation: Repeat lumbar puncture for CSF HSV DNA PCR at day 14 to 21, near the conclusion of therapy.
   • Rationale: Acyclovir must never be discontinued until HSV PCR in CSF is documented to be negative. If the PCR remains positive, acyclovir must be continued and CSF re-tested weekly until negative, as premature cessation carries a high risk of clinical relapse and progressive neurodevelopmental devastation.

1. Diagnosis, Pathogen & Rash Mechanism:
   • Diagnosis: Infectious Mononucleosis (Glandular Fever).
   • Causative Organism: Epstein-Barr Virus (EBV) (Human Gammaherpesvirus 4).
   • Mechanism of Eruption: Aminopenicillin-induced rash (non-IgE-mediated delayed hypersensitivity reaction). Polyclonal B-cell activation driven by EBV enhances cell-mediated immune responses to aminopenicillins (ampicillin/amoxicillin). This does not signify a true, permanent beta-lactam allergy.
2. Peripheral Blood Smear Findings:
   • Atypical Lymphocytes (Downey Cells): Large, pleomorphic, activated cytotoxic CD8+ T lymphocytes with abundant basophilic cytoplasm scalloping around adjacent red blood cells.
   • Diagnostic Threshold: Absolute lymphocytosis ($>50\%$ of total white blood cell count) with $\ge 10\%$ atypical lymphocytes.
3. Serologic Profile Interpretation:
   • Profile A [VCA IgM (+), VCA IgG (+), EBNA IgG (-)]: Confirms acute, primary EBV infection (anti-EBNA antibodies develop late, typically 2–4 months post-infection, and remain for life).
   • Profile B [VCA IgM (-), VCA IgG (+), EBNA IgG (+)]: Indicates past, remote EBV infection with established lifelong immunity.
4. Activity Restrictions & Corticosteroid Indications:
   • Physical Activity Restriction:
     • Strict avoidance of contact sports and vigorous heavy lifting for at least 3 to 4 weeks from symptom onset (or until splenomegaly has completely resolved on clinical examination/ultrasound) to prevent life-threatening splenic rupture.
   • Indications for Systemic Corticosteroids (e.g., Prednisolone $1\text{ mg/kg/day}$ for 5–7 days, tapered):
     • Impending upper airway obstruction due to massive tonsillar hypertrophy and pharyngeal edema.
     • Severe autoimmune hemolytic anemia or immune thrombocytopenic purpura (ITP).
     • Severe neurologic complications (encephalitis, Guillain-Barré syndrome, cranial nerve palsies).

1. Secondary Bacterial Pathogens & Clinical Warning Signs:
   • Bacterial Pathogens:
     • Streptococcus pneumoniae (most common overall).
     • Staphylococcus aureus (including Methicillin-Resistant S. aureus [MRSA] which causes severe necrotizing pneumonia).
     • Streptococcus pyogenes (Group A Streptococcus).
   • Clinical Warning Signs ("Double Sickening"):
     • Biphasic fever curve: Recrudescence of high fever after an initial 2- to 3-day period of clinical improvement.
     • Recurrence of respiratory distress with tachypnea, focal crepitations, bronchial breath sounds, or consolidation on chest radiography.
2. Characteristics of Pandemic 2009 A/H1N1:
   • Quadruple Reassortant Genome: Possesses a unique combination of gene segments from North American swine, North American avian, human seasonal influenza, and Eurasian swine influenza viruses.
   • Altered Age-Demographic Mortality: Disproportionately affected children, young adults, and pregnant women due to lack of preexisting cross-reactive neutralizing antibodies (unlike older adults born before 1957 who possessed partial immunity).
3. Pediatric Extra-Pulmonary Complications:
   • Acute Myositis / Rhabdomyolysis (typically presenting as calf tenderness and refusal to bear weight; common with Influenza B).
   • Neurological complications: Febrile seizures, Acute Necrotizing Encephalopathy of childhood (ANE), and Guillain-Barré syndrome.
   • Acute Myocarditis / Pericarditis with arrhythmias or cardiogenic shock.
   • Reye syndrome (rapidly progressive encephalopathy with hepatic dysfunction, specifically if exposed to aspirin/salicylates).
4. Oral Antiviral Therapy (Oseltamivir):
   • Agent: Oral Oseltamivir (Neuraminidase inhibitor).
   • Duration: 5-day course given twice daily (BID).
   • Weight-Based Dosing Schedule (Children $\ge 1\text{ year}$):
     • $\le 15\text{ kg}$: $30\text{ mg}$ PO BID.
     • $>15\text{ to }23\text{ kg}$: $45\text{ mg}$ PO BID.
     • $>23\text{ to }40\text{ kg}$: $60\text{ mg}$ PO BID.
     • $>40\text{ kg}$: $75\text{ mg}$ PO BID.
   • Initiation Window: Optimal efficacy when initiated within $\le 48\text{ hours}$ of symptom onset (benefit still exists in severe/hospitalized/immunocompromised children initiated beyond 48 hours).
   • Clinical Benefits:
     • Shortens symptom duration by approximately 1 to 1.5 days.
     • Significantly reduces secondary complications (such as acute otitis media by up to 50% and lower respiratory tract infections requiring antibiotics).
     • Shortens the duration of viral shedding and reduces hospital length of stay.

1. Recommended Vaccination Schedule & Dosing:
   • Dose Requirement: The child requires 2 doses of the current season's quadrivalent inactivated influenza vaccine (QIV) administered at a minimum interval of 4 weeks apart.
   • Rationale: Children aged 6 months through 8 years who have not previously received $\ge 2$ lifetime doses of influenza vaccine (or whose vaccination history is unknown/incomplete) require a 2-dose primary series in the current season.
   • Dose Volume & Route: $0.5\text{ mL}$ (15 $\mu\text{g}$ hemagglutinin per strain) administered via the intramuscular (IM) route into the anterolateral thigh or deltoid muscle.
2. Types of Influenza Vaccines & Approved Age Limits:
   • Inactivated Influenza Vaccine (IIV / QIV): Administered intramuscularly; approved for infants $\ge 6\text{ months}$ of age.
   • Live Attenuated Influenza Vaccine (LAIV): Administered intranasally (cold-adapted, temperature-sensitive); approved for healthy children $\ge 2\text{ years}$ up to 49 years of age (contraindicated in children $<2$ years, immunocompromised individuals, severe asthmatics, and children on long-term aspirin therapy).
3. Antigenic Composition of Quadrivalent Vaccines:
   • Influenza A (H1N1) strain (e.g., A/Victoria-like).
   • Influenza A (H3N2) strain (e.g., A/Darwin-like).
   • Influenza B (Yamagata lineage) strain.
   • Influenza B (Victoria lineage) strain.
     (Note: WHO has recommended transitioning to trivalent formulations by excluding the B/Yamagata lineage as it has not been detected in global surveillance since March 2020).
4. Factors Determining Vaccine Efficacy:
   • Antigenic Match: Degree of antigenic concordance between the circulating seasonal wild-type strains and the vaccine seed strains chosen by WHO.
   • Host Immune Status & Age: Prior natural exposure, immune maturity, underlying primary or secondary immunodeficiency, and nutritional status.
   • Interval from Vaccination (Waning Immunity): Gradual decay of protective serum hemagglutination inhibition (HI) antibody titers over 6–12 months post-immunization.
5. Optimal Vaccination Timing in India (IAP Recommendations):
   • Southern India & Regions with Southwest Monsoon (e.g., Maharashtra, Kerala, coastal states): Peak influenza activity occurs during the monsoon; vaccination is recommended in April to May (utilizing the Southern Hemisphere formulation).
   • Northern India (e.g., Delhi, Kashmir, Punjab, plains with winter peaks): Peak influenza activity occurs during winter (December–February); vaccination is recommended in October to November (utilizing the Northern Hemisphere formulation).

1. Definitive Diagnosis & Causative Organism:
   • Diagnosis: Intestinal ascariasis (heavy roundworm infestation).
   • Causative Organism: Ascaris lumbricoides (phylum Nematoda).
2. Surgical Complications of Heavy Infestation:
   • Mechanical Intestinal Obstruction: Intraluminal massing of coiled adult worms (bolus) obstructing the terminal ileum or ileocecal junction.
   • Intussusception: Worm bolus acting as a lead point for ileocecal or ileoileal invagination.
   • Biliary & Pancreatic Ascariasis: Migration of worms through the ampulla of Vater causing obstructive jaundice, acute cholangitis, hepatic abscesses, or acute necrotizing pancreatitis.
   • Bowel Perforation and Gangrene: Ischemic pressure necrosis of the intestinal wall leading to generalized peritonitis.
   • Acute Appendicitis / Meckel Diverticulitis: Worm entrapment causing luminal obstruction.
3. Mathematical Derivation & Dosing Protocol:
   $$ > \begin{aligned} > \text{Child Age} &= 3\text{ years} \quad (\text{Age } \ge 2\text{ years}) \\ > \text{Therapeutic Dose (Albendazole)} &= \mathbf{400\text{ mg}} \text{ orally as a single stat dose} \\ > \text{Alternative Regimen} &= \text{Albendazole } 400\text{ mg once daily for 3 consecutive days (heavy load)} \\ > \text{Prophylactic Mass Deworming} &= \mathbf{400\text{ mg}} \text{ orally every 6 months} \quad (\ge 2\text{ years of age}) > \end{aligned} > $$
   (Note: For children aged 12–23 months, the standard single dose of albendazole is $200\text{ mg}$; for $\ge 24\text{ months}$, it is $400\text{ mg}$).
4. Conservative Medical Management of Non-Strangulated Partial Obstruction:
   • Gastrointestinal Decompression & Rest: Keep child nil per os (NPO) and place a wide-bore nasogastric (NG) tube on continuous free drainage and intermittent low suction.
   • Intravenous Fluid & Electrolyte Resuscitation: Correct dehydration, hypokalemia, and metabolic alkalosis using balanced isotonic crystalloids.
   • Anthelmintic Selection & Timing: Avoid neurotoxic vermicidal drugs (like pyrantel pamoate which produces spastic paralysis of worms, worsening compaction); administer Piperazine citrate ($75\text{ mg/kg}$ orally/via NG tube, max $3.5\text{ g}$) to induce flaccid neuromuscular paralysis of worms, or withhold anthelmintics until acute obstruction resolves.
   • Intraluminal Lubrication: Instill warm saline or mineral oil (liquid paraffin, $1\text{–}2\text{ mL/kg}$) via the nasogastric tube to lubricate and break up the worm aggregation.
   • Serial Clinical & Abdominal Monitoring: Serial physical exams, abdominal girth measurements, and serial erect abdominal radiographs; proceed to emergency laparotomy if fever, peritonism, rebound tenderness, or pneumoperitoneum develops.
5. Pulmonary Migration Phase & Cardinal Triad:
   • Syndrome: Löffler syndrome (transient eosinophilic pneumonitis).
   • Cardinal Triad:
     • Dry paroxysmal cough with wheezing/dyspnea.
     • Transient, migratory pulmonary infiltrates on chest radiography.
     • Marked peripheral blood eosinophilia ($\ge 500\text{–}1000/\mu\text{L}$).

1. Diagnoses:
   • Infant A: Irritant Diaper Dermatitis (Contact / Ammoniacal diaper dermatitis).
   • Infant B: Candidal Diaper Dermatitis (Candida albicans cutaneous infection / Moniliasis).
2. Pathophysiology of Irritant Diaper Dermatitis (Infant A):
   • Prolonged Moisture & Maceration: Occlusion by wet diapers disrupts the stratum corneum barrier, increasing skin permeability and friction-induced micro-trauma.
   • Elevated Local pH: Fecal bacterial ureases hydrolyze urinary urea into free ammonia, which raises the skin microenvironment pH.
   • Enzymatic Activation: The elevated alkaline pH activates fecal proteases (trypsin, chymotrypsin) and lipases, causing chemical irritation and epithelial barrier breakdown on convex contact areas.
3. Pathognomonic Lesions of Infant B:
   • Satellite lesions: Small, discrete pinpoint erythematous papules and pustules extending beyond the margins of the central plaque.
   • Involvement of genitocrural skin folds: Deep intertriginous flexural maceration with a distinct collarette of scale.
4. Management Plan for Infant A (Irritant Diaper Dermatitis):
   • Non-Pharmacological (The "ABCDE" approach):
     • A (Air): Keep diaper-free for prolonged periods (hours daily) to facilitate drying.
     • B (Barrier): Apply thick barrier ointments containing Zinc oxide (10–40%) or White soft paraffin / Petrolatum with every diaper change.
     • C (Cleansing): Gentle cleansing with lukewarm water and soft cotton cloth; avoid alcohol- or fragrance-containing wet wipes; pat dry without scrubbing.
     • D (Diaper): Frequent diaper changes (every 2–3 hours or immediately after defecation) using highly absorbent gel-matrix diapers.
     • E (Education): Parental counseling on hygiene and avoiding tight strapping.
   • Pharmacological (if severe inflammation): Short course of mild low-potency topical corticosteroid: 1% Hydrocortisone cream applied sparingly twice daily for a maximum of 3–5 days.
5. Topical Pharmacological Regimen for Infant B (Candidal Dermatitis):
   • First-line Topical Antifungal:
     • Clotrimazole (1% cream) OR Miconazole (2% cream) OR Nystatin ointment (100,000 units/g).
     • Application Protocol: Apply a thin layer directly to the affected plaques and satellite lesions 2 to 3 times daily after cleansing.
     • Duration: Continue for 7 to 14 days (or at least 48 to 72 hours after complete clinical resolution of the rash).
     • Cover with a barrier layer of zinc oxide over the antifungal cream to protect from further friction and maceration.

1. Syndromic & Definitive Diagnosis:
   • Syndromic Diagnosis: Acute Encephalitis Syndrome (AES).
   • Definitive Etiology: Japanese Encephalitis (JE) (caused by Japanese Encephalitis Virus [JEV], an arthropod-borne single-stranded positive-sense RNA Flavivirus).
2. Vector and Reservoir Hosts:
   • Primary Mosquito Vector: Culex tritaeniorhynchus (along with Culex vishnui complex, breeding abundantly in stagnant water of flooded rice paddy fields).
   • Amplifying Host: Pigs (high viremia without clinical illness; natural amplifier) and Ardeid wading birds (herons, egrets; maintenance reservoir).
   • Note: Humans and horses are accidental, dead-end hosts because viremia levels are insufficient to infect biting mosquitoes.
3. Classic Anatomical Targets on Neuroimaging (MRI Brain):
   • Thalami (classically bilateral symmetrical thalamic involvement, with high T2/FLAIR hyperintensity and microhemorrhages).
   • Basal ganglia (putamen, caudate, globus pallidus).
   • Substantia nigra and midbrain.
   • Temporal lobes, pons, and anterior horns of the spinal cord (polio-like lower motor neuron involvement).
4. Diagnostic Investigation of Choice:
   • Test: IgM Antibody Capture Enzyme-Linked Immunosorbent Assay (MAC-ELISA).
   • Clinical Specimen: Cerebrospinal fluid (CSF) (preferred, higher diagnostic yield and specificity) or Serum.
   • Optimal Timing: CSF collected between day 3 and day 10 post-onset of symptoms (reaches $>90\%$ sensitivity by day 7); serum collected after day 7 (paired acute and convalescent sera demonstrate $\ge 4$-fold titer rise).
5. Vaccines & UIP Schedule in India:
   • Vaccine Types:
     • Live Attenuated Vaccine: Cell-culture derived SA-14-14-2 strain (freeze-dried, administered subcutaneously).
     • Inactivated Vaccine: Vero cell-derived inactivated vaccine (e.g., JENVAC, IC51) or tissue-culture purified vaccine.
   • National Immunization Schedule (UIP endemic districts):
     • First Dose (JE-1): At 9 completed months to 12 months of age ($0.5\text{ mL}$ subcutaneous in right upper arm, co-administered with MR-1).
     • Second Dose (JE-2): At 16 to 24 months of age ($0.5\text{ mL}$ subcutaneous, co-administered with DPT booster-1 and MR-2).

1. Diagnosis, Etiology & Reservoir:
   • Diagnosis: Leptospirosis (Anicteric form / Acute leptospiremic phase).
   • Causative Microorganism: Leptospira interrogans (pathogenic, tightly coiled, spirochete bacterium).
   • Primary Animal Reservoir: Rodents (rats, mice), which carry the organism asymptomatically in renal tubules and shed large bacterial loads in their urine, contaminating stagnant water and moist soil.
2. Severe Form & Classic Triad:
   • Term: Weil's Disease (or Weil's syndrome / severe icteric leptospirosis).
   • Classic Triad:
     • Deep jaundice with hepatic dysfunction (conjugated hyperbilirubinemia).
     • Acute renal failure (oliguria/anuria with acute tubular necrosis).
     • Hemorrhagic manifestations (pulmonary hemorrhage, gastrointestinal bleeding, purpura).
3. Confirmatory Laboratory Test & Criteria:
   • Test: Microscopic Agglutination Test (MAT) (using live panels of pathogenic Leptospira serovars).
   • Diagnostic Criteria:
     • A four-fold or greater rise in agglutination antibody titers between acute- and convalescent-phase serum specimens; OR
     • A single high reciprocal MAT titer of $\ge 1:400$ (or $\ge 1:800$ in hyperendemic regions) in the presence of a compatible clinical illness.
4. Expected Laboratory Abnormalities:
   • Complete Blood Count: Marked polymorphonuclear leukocytosis with left shift; significant thrombocytopenia ($<100,000/\mu\text{L}$) and elevated ESR/CRP.
   • Liver Function Tests: Conjugated hyperbilirubinemia with disproportionately mild-to-moderate transaminitis (AST/ALT typically $<200\text{–}300\text{ IU/L}$, contrasting with viral hepatitis where titers reach thousands).
   • Renal Function Tests: Elevated serum urea and creatinine; urine microscopy reveals proteinuria, microscopic hematuria, and pyuria with casts (hypokalemia or normokalemia is typical in non-oliguric renal failure due to tubular wasting).
   • Muscle Enzymes: Markedly elevated serum Creatine Phosphokinase (CPK), often $>1000\text{ IU/L}$ (reflecting rhabdomyolysis and severe myositis).
5. Antimicrobial Treatment Regimen:
   $$ > \begin{aligned} > \text{Drug of Choice (IV)} &= \text{Crystalline Cefotaxime / Ceftriaxone OR Crystalline Penicillin G} \\ > \text{IV Ceftriaxone Regimen} &= 80\text{–}100\text{ mg/kg/day IV once daily (or divided q12h)} \\ > \text{Dose for } 20\text{ kg child} &= 20\text{ kg} \times 100\text{ mg/kg/day} = \mathbf{2000\text{ mg (2 g) IV once daily for 7 days}} \\ > \text{Alternative: Penicillin G} &= 250,000\text{–}400,000\text{ units/kg/day IV in divided doses every 4 to 6 hours} \\ > \text{Dose for } 20\text{ kg child} &= 20\text{ kg} \times 300,000\text{ units} = \mathbf{6,000,000\text{ units/day (1,000,000 units IV q4h) for 7 days}} > \end{aligned} > $$
6. Anticipated Complication on Treatment Initiation:
   • Jarisch-Herxheimer Reaction (JHR): Characterized by acute onset of rigors, sudden rise in body temperature, worsening tachycardia, hypotension, and exacerbation of rash/myalgia, occurring within 1–12 hours after the first dose of antibiotics due to massive spirochetal lysis and cytokine release (TNF-$\alpha$, IL-6, IL-8). Managed supportively with IV fluids, antipyretics, and vasopressors if refractory.

1. Definition of Drug-Sensitive Malaria:
   • Complete clearance of asexual parasitemia by Day 6 following the initiation of standard antimalarial therapy, without subsequent recrudescence of asexual parasites through Day 28 (or Day 42, depending on the elimination half-life of the partner companion drug).
2. WHO Grades of Antimalarial Drug Resistance:
   • RI Resistance (Late Recrudescence):
     • Clearance of asexual parasitemia by Day 6 of therapy, followed by recrudescence of parasitemia between Day 7 and Day 28.
     • Subclassified into Early Recrudescence (parasitemia reappears between Day 7 and Day 14) and Late Recrudescence (parasitemia reappears between Day 15 and Day 28).
   • RII Resistance (Early Resistance):
     • Significant reduction of asexual parasitemia (>75% reduction from baseline) at 48 hours after initiating therapy, but failure to achieve complete clearance by Day 6.
   • RIII Resistance (High-Level Resistance):
     • Little or no reduction in asexual parasitemia (<75% reduction from baseline) at 48 hours, or an increase in asexual parasite count at 48 hours compared to baseline.
3. Indications and Dosing for Primaquine:
   • Plasmodium falciparum (Gametocytocidal therapy):
     • Indication: To clear mature stage V gametocytes and prevent vector transmission of drug-resistant strains.
     • Dosage: 0.25 mg base/kg (single dose) orally on Day 2 of ACT (National Vector Borne Disease Control Programme [NVBDCP] recommends 0.75 mg base/kg single dose on Day 2).
     • Safety/Contraindications: Routine G6PD screening is not mandatory for a single 0.25 mg/kg dose; contraindicated in infants <6 months, pregnant females, and lactating mothers of infants <6 months.
   • Plasmodium vivax / Plasmodium ovale (Anti-relapse / Radical cure):
     • Indication: Elimination of dormant intrahepatic hypnozoites to prevent clinical relapses.
     • Dosage: 0.25 mg to 0.5 mg base/kg/day orally once daily for 14 days, administered concurrently with food.
     • Safety/Contraindications: Mandatory screening for Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency prior to therapy. In mild-to-moderate G6PD deficiency, modify to 0.75 mg base/kg once weekly for 8 consecutive weeks under close clinical and hematologic monitoring. Strictly contraindicated in severe G6PD deficiency, pregnancy, and infants <6 months.

graph TD
    A[Suspected Antimalarial Resistance] --> B[Asexual Parasite Count at 48 Hours]
    B -->|>= 75% Clearance| C[Smear on Day 6]
    B -->|< 75% Clearance or Count Rising| D[Grade RIII Resistance]
    C -->|Parasitemia Present on Day 6| E[Grade RII Resistance]
    C -->|Cleared by Day 6| F[Monitor Weekly to Day 28]
    F -->|No Recrudescence by Day 28| G[Drug Sensitive Malaria]
    F -->|Recrudescence between Day 7 and 28| H[Grade RI Resistance]

1. Confirmation of Acute Maternal Rubella Infection:
   • Detection of rubella-specific IgM antibodies in acute-phase serum drawn within 7 to 28 days of rash onset.
   • Demonstration of a ≥4-fold increase in rubella-specific IgG antibody titers between paired sera drawn 2 to 3 weeks apart (acute and convalescent samples run concurrently in the same assay).
   • Low IgG avidity index (<30–50%, depending on assay platform) in the presence of IgG, indicating an acute primary infection within the preceding 2 months.
2. Distinguishing Preexisting Immunity from Primary Infection:
   • Preexisting Immunity: Presence of rubella-specific IgG antibodies accompanied by absent rubella-specific IgM antibodies in a serum sample collected within 3 days of rash onset, corroborated by a high IgG avidity index (>60%).
   • Primary Infection: Absence of IgG with emerging IgM in the first 72 hours, followed by rapid IgG seroconversion with low avidity.
3. Transmission Rate and Fetal Sequelae Risk at 6 Weeks:
   • Maternal-Fetal Transmission Risk: Approximately 80% to 90% during the first 8 weeks of gestation.
   • Risk of Congenital Defects (Congenital Rubella Syndrome - CRS): Up to 85% to 90% risk of multi-organ embryopathy (classic triad of sensorineural hearing loss, congenital cataract/microphthalmia, and congenital heart disease [patent ductus arteriosus, peripheral pulmonary stenosis], alongside microcephaly and intrauterine growth restriction).
4. Management and Counseling:
   • Counseling & Pregnancy Management: Provide detailed non-directive counseling regarding the high risk of catastrophic embryopathy. In accordance with the Medical Termination of Pregnancy (MTP) Act, therapeutic termination of pregnancy should be strongly offered and facilitated given gestation is <24 weeks.
   • Intrauterine Diagnostic Confirmation: If the patient opts to continue gestation, amniocentesis after 16–18 weeks for rubella virus RT-PCR in amniotic fluid can verify fetal infection (does not quantify structural severity).
   • Immunization Recommendation: Live attenuated rubella vaccine (RA 27/3) is strictly contraindicated during pregnancy. If pregnancy is terminated or if susceptible non-pregnant, administer MMR/Rubella vaccine with advice to avoid conception for at least 4 weeks (28 days).

1. Diagnosis & Microbial Morphology:
   • Clinical Syndrome: Meningococcemia / Purpura fulminans / Fulminant meningococcal septic shock.
   • Etiologic Organism: Neisseria meningitidis (Meningococcus).
   • Morphology: Gram-negative, non-sporing, non-motile, kidney-shaped or coffee-bean-shaped diplococci with flattened opposing margins, seen both intracellularly within polymorphonuclear leukocytes and extracellularly.
2. Immediate Resuscitation & Antimicrobial Regimen:
   • Fluid Resuscitation:
     • Rapid infusion of balanced crystalloids (e.g., Plasmalyte or Ringer Lactate) at 10–20 mL/kg over 10–20 minutes with frequent reassessment for signs of fluid overload (hepatomegaly, crackles).
     • Early peripheral or central initiation of vasoactive infusions (Norepinephrine 0.05–1 µg/kg/min for warm/vasodilatory shock or Epinephrine 0.05–0.3 µg/kg/min for cold shock) within the first hour for fluid-refractory shock.
   • Empirical Antimicrobial Therapy:
     • IV Ceftriaxone: 100 mg/kg/day IV divided every 12 hours (maximum 4 g/day), OR
     • IV Cefotaxime: 200 mg/kg/day IV divided every 6 hours (maximum 12 g/day).
     • Duration: 7 days.
3. Endocrine Complication:
   • Waterhouse-Friderichsen Syndrome (Acute adrenal hemorrhagic infarction leading to acute primary adrenal insufficiency / adrenal crisis).
   • Managed with stress-dose corticosteroids: IV Hydrocortisone 50–100 mg/m²/day (or 2 mg/kg IV loading dose followed by 1–2 mg/kg IV every 6 hours).
4. Chemoprophylaxis for Close Contacts:
   • Rifampicin (First-line):
     • Dose: 10 mg/kg/dose orally every 12 hours for 2 days (4 doses total); maximum 600 mg/dose. (Infants <1 month: 5 mg/kg/dose every 12 hours for 2 days).
   • Ceftriaxone (Alternative / Preferred in pregnancy):
     • Single dose intramuscularly: 125 mg IM for children <15 years; 250 mg IM for children ≥15 years and adults.
   • Ciprofloxacin (Alternative for adults/older adolescents):
     • Single oral dose: 20 mg/kg (maximum 500 mg).
   • Azithromycin (Alternative):
     • Single oral dose: 10 mg/kg (maximum 500 mg).

graph TD
    A[Fulminant Meningococcal Septic Shock] --> B[Immediate Resuscitation within First Hour]
    B --> C[Rapid Crystalloid 10-20 mL/kg Boluses]
    B --> D[Immediate IV Ceftriaxone 100 mg/kg/day]
    B --> E[Early Inotrope / Vasopressor Infusion]
    E -->|Refractory Hypotension / Suspected Waterhouse-Friderichsen| F[Stress-dose Hydrocortisone 50-100 mg/m2/day]
    A --> G[Public Health Notification & Tracing]
    G --> H[Chemoprophylaxis to Close Contacts within 24 Hours]
    H --> I[Oral Rifampicin 10 mg/kg BID x 2 Days OR Single-dose Ceftriaxone/Ciprofloxacin]

1. Group A:
   • Odd One Out: Neisseria meningitidis.
   • Scientific Justification: Neisseria meningitidis is a Gram-negative diplococcus, whereas Enterococcus faecalis (Gram-positive coccus), Corynebacterium diphtheriae (Gram-positive non-sporing pleomorphic bacillus), and Clostridium tetani (Gram-positive spore-forming anaerobic bacillus) are all Gram-positive bacteria.
2. Group B:
   • Odd One Out: High-dose Azithromycin.
   • Scientific Justification: Azithromycin is fundamentally a bacteriostatic antibiotic (macrolide class that reversibly binds the 50S ribosomal subunit inhibiting transpeptidation and translocation), whereas Ceftazidime (third-generation cephalosporin), Teicoplanin (glycopeptide), and Aztreonam (monobactam) are bactericidal agents that act directly to disrupt bacterial cell-wall synthesis.
3. Group C:
   • Odd One Out: Linezolid resistance.
   • Scientific Justification: Linezolid resistance is a target-site ribosomal mutation (23S rRNA domain V mutation or plasmid-mediated cfr methyltransferase) that occurs in Gram-positive cocci (e.g., VRE, MRSA). In contrast, ESBL production, AmpC induction, and NDM-1 metallo-beta-lactamase are enzymatic cleavage mechanisms characteristic of multidrug-resistant Gram-negative bacilli (Enterobacterales and non-fermenting bacilli).
4. Group D:
   • Odd One Out: Cryptococcal antigen latex agglutination.
   • Scientific Justification: Cryptococcal antigen latex agglutination is a direct microbial antigen detection test (detecting glucuronoxylomannan capsular polysaccharide of Cryptococcus neoformans). In contrast, the Weil-Felix, Widal, and Paul-Bunnell tests are indirect serological antibody detection tests that rely on heterophile or agglutinating host antibody responses (Weil-Felix uses Proteus antigens for rickettsiae, Paul-Bunnell uses sheep erythrocytes for EBV, and Widal detects agglutinating antibodies against Salmonella O and H antigens).

1. Clinical Diagnosis:
   • Mastitis neonatorum complicated by neonatal breast abscess.
2. Causative Organism & Route:
   • Most Common Organism: Staphylococcus aureus (accounting for >75–85% of cases; includes both Methicillin-Susceptible [MSSA] and Methicillin-Resistant S. aureus [MRSA]).
   • Route of Acquisition: Ascending canalicular infection through the nipple lactiferous ducts, inoculated from maternal or infant colonizing skin flora, directly provoked by microtrauma and ductal disruption secondary to breast bud squeezing or manipulation.
3. Complications:
   • Local Complications:
     • Destruction of the primordial breast bud and glandular tissue, leading to permanent breast hypoplasia or amastia in adulthood.
     • Necrotizing fasciitis of the anterior chest wall.
     • Severe scarring and nipple-areolar complex deformities.
   • Systemic Complications:
     • Staphylococcal bacteremia and septicemia.
     • Hematogenous seeding leading to osteomyelitis, septic arthritis, or deep organ abscesses.
4. Management Plan:
   • Medical Therapy:
     • Hospitalization for parenteral antimicrobials.
     • Empirical IV therapy targeting S. aureus: IV Cloxacillin (100–150 mg/kg/day divided every 6 to 8 hours) plus an aminoglycoside (IV Amikacin 15 mg/kg/day once daily); OR IV Vancomycin (15 mg/kg/dose every 8–12 hours) if community

1. Lesion Description & Diagnosis:
   • Description: Diffuse, elevated, creamy-white to yellowish curdy plaques ("cottage-cheese" appearance) distributed over the buccal mucosa, gingiva, hard palate, and dorsal tongue, which leave an erythematous, raw, bleeding mucosal base upon scraping (distinguishing them from inert residual milk curds).
   • Diagnosis: Oral thrush (Acute pseudomembranous candidiasis).
2. Causative Agent & Microscopic Appearance:
   • Organism: Candida albicans (most common; non-albicans species include C. tropicalis, C. parapsilosis, and C. glabrata).
   • 10% KOH Mount: Budding oval yeast cells (blastoconidia) with characteristic branching pseudohyphae and true hyphae.
3. Predisposing Factors:
   • Recent exposure to broad-spectrum oral antibiotics (disruption of competitive normal oral bacterial flora).
   • Use of inhaled corticosteroids without a valved holding chamber (spacer) or mouth rinsing.
   • Poor bottle hygiene, unsterilized nipples, or prolonged pacifier use.
   • Underlying cellular immunodeficiency (e.g., Severe Combined Immunodeficiency [SCID], pediatric HIV/AIDS, DiGeorge syndrome).
   • Severe acute malnutrition (SAM) or chronic systemic disease.
4. Pharmacological Management:
   • First-line Topical Therapy:
     • Clotrimazole oral gel / troche: 1% oral gel applied topically 3–4 times daily, OR
     • Nystatin oral suspension: 100,000 units/mL; dose is 100,000 to 200,000 units (1–2 mL) topically to oral mucosa 4 times daily (after feeds) divided equally on each side of the mouth for 7–14 days (or until 48 hours after complete clinical resolution).
     • Concurrent Measure: Decontamination/sterilization of bottle teats and pacifiers; application of topical antifungal cream to mother's nipples if actively breastfeeding.
   • Systemic Therapy (Refractory / Immunocompromised):
     • Fluconazole oral suspension: Loading dose of 6 mg/kg on day 1, followed by 3 mg/kg/day once daily for 7 to 14 days (maximum 200 mg/day).

1. Diagnosis & Anatomic Boundary:
   • Diagnosis: Orbital cellulitis (Postseptal cellulitis).
   • Anatomic Landmark: The orbital septum (a fibrous membrane extending from the periosteum of the orbital rim into the tarsal plates of the eyelids). Postseptal infections involve structures posterior to this barrier within the bony orbit.
2. Differentiating Clinical Findings (Orbital vs. Preseptal):
   • Proptosis (axial protrusion of the globe).
   • Ophthalmoplegia (painful restriction/limitation of extraocular eye movements).
   • Decreased visual acuity or loss of color vision.
   • Relative afferent pupillary defect (RAPD) indicating optic nerve compression.
   • Chemosis (marked conjunctival edema and injection).
     (Note: Preseptal cellulitis exhibits superficial eyelid edema and erythema with completely preserved globe motility, normal vision, no proptosis, and no pupillary defect).
3. Source of Infection & Causative Pathogens:
   • Anatomical Route: Direct contiguous extension from acute or chronic paranasal sinusitis, most frequently ethmoid sinusitis traversing the thin, porous lamina papyracea and valveless ophthalmic veins.
   • Pathogens:
     • Staphylococcus aureus (including Methicillin-resistant S. aureus [MRSA]).
     • Streptococcus pneumoniae.
     • Streptococcus pyogenes (Group A Streptococcus).
     • Anaerobic oral flora (Peptostreptococcus, Fusobacterium, Bacteroides) in older children / polymicrobial odontogenic or chronic sinusitis.
4. Imaging, Empirical Antibiotics & Surgical Indications:
   • Imaging of Choice: Contrast-Enhanced Computed Tomography (CECT) of the orbits, paranasal sinuses, and brain (axial and coronal fine cuts).
   • Intravenous Antibiotic Regimen:
     • IV Ceftriaxone: 100 mg/kg/day IV divided q12h (or IV Cefotaxime 200 mg/kg/day divided q6–8h; max 4 g/day), PLUS
     • IV Vancomycin: 40–60 mg/kg/day IV divided q6h (max 2 g/day; targeting MRSA), PLUS
     • IV Metronidazole: 30 mg/kg/day IV divided q8h (if anaerobic dental or chronic sinus source suspected).
   • Indications for Emergent Surgical Decompression:
     • Radiologically confirmed well-defined subperiosteal abscess (SPA) or orbital abscess, particularly with intracranial extension or large volume (width >4 mm / volume >0.5–1 mL).
     • Evidence of progressive optic neuropathy (declining visual acuity or worsening RAPD).
     • Lack of clinical improvement or worsening proptosis/fever after 24 to 48 hours of appropriate intravenous antimicrobials.
     • Abnormally elevated intraocular pressure (>20–30 mmHg) threatening retinal perfusion.

flowchart TD
    A[Child with Acute Periorbital Swelling and Fever] --> B{Proptosis, Ophthalmoplegia, RAPD, or Reduced Vision?}
    B -- No --> C[Preseptal Cellulitis]
    C --> D[Oral/IV Antibiotics + Close Outpatient/Inpatient Review]
    B -- Yes --> E[Orbital Cellulitis Postseptal]
    E --> F[Urgent Emergent CECT Orbits and Sinuses]
    F --> G[Start IV Ceftriaxone + Vancomycin +/- Metronidazole]
    G --> H{Large Abscess, Visual Decline, or Non-responsive at 24-

1. Disease-Pathogen Matching:

   • 1 $\rightarrow$ B (Burkholderia pseudomallei)
   • 2 $\rightarrow$ E (Legionella pneumophila)
   • 3 $\rightarrow$ A (Bartonella bacilliformis)
   • 4 $\rightarrow$ D (Mycobacterium marinum)
   • 5 $\rightarrow$ C (Coxsackievirus B)
   • 6 $\rightarrow$ F (Bartonella henselae)

2. Differentiating Features of Pontiac Fever vs. Legionnaires' Disease:

   • (a) Incubation Period: Pontiac fever has a short incubation of 24–48 hours (range: 6–72 hours); Legionnaires' disease has a longer incubation of 2–10 days (up to 14 days).
   • (b) Clinical Attack Rate: Pontiac fever has a high attack rate (>90%); Legionnaires' disease has a low attack rate (<5%).
   • (c) Pulmonary Involvement: Pontiac fever presents as a self-limiting, flu-like illness without pneumonia (chest radiograph is normal); Legionnaires' disease presents with severe multi-lobar necrotizing pneumonia, alveolar consolidation, and pleural effusion.
   • (d) Antibiotic Therapy: Pontiac fever is self-limited and resolves within 2–5 days without antimicrobial treatment; Legionnaires' disease requires targeted IV/oral macrolides (Azithromycin) or respiratory fluoroquinolones (Levofloxacin).

3. Mathematical Derivation of Blood Culture Volume Safety:
   

   $$ > \begin{aligned} > \text{Total Circulating Blood Volume (TCBV)} &= \text{Body Weight (kg)} \times 80\text{ mL/kg} \\ > &= 12\text{ kg} \times 80\text{ mL/kg} = \mathbf{960\text{ mL}} \\[1ex] > \text{Percentage of TCBV Sampled} &= \left( \frac{\text{Sampled Volume}}{\text{TCBV}} \right) \times 100 \\ > &= \left( \frac{10\text{ mL}}{960\text{ mL}} \right) \times 100 \\ > &= \mathbf{1.04\%} \quad (\text{Safe Threshold: } < 3.0\%; \text{ Target Optimal: } 1\% - 2.5\%) > \end{aligned} > $$
   • Clinical Interpretation: Sampling 10 mL constitutes 1.04% of total blood volume, which is strictly safe while ensuring optimal diagnostic sensitivity (>90% yield).

4. Procedural Checklist for Sterile Peripheral Blood Culture Collection:

   • Step 1: Preparation & Hand Hygiene: Perform strict hand hygiene with soap and water or alcohol hand rub; don clean non-sterile gloves for vein assessment, then switch to sterile gloves for the procedure.
   • Step 2: Bottle Septum Disinfection: Remove caps from culture bottles and clean the rubber septa with 70% isopropyl alcohol for 15 seconds; allow to air dry completely (do not use povidone-iodine on rubber septa).
   • Step 3: Skin Antisepsis: Disinfect venipuncture site using 2% chlorhexidine gluconate (CHG) in 70% isopropyl alcohol (for children $\ge 2$ months) with a vigorous back-and-forth friction scrub for $\ge 30$ seconds; allow to dry completely for $\ge 2$ minutes (do not palpate the vein after antisepsis unless using sterile gloves).
   • Step 4: Venipuncture & Blood Aspiration: Perform peripheral direct venipuncture using a sterile butterfly needle or syringe; aspirate the exact age-/weight-appropriate blood volume. Avoid drawing through an indwelling intravenous cannula unless suspecting catheter-related bloodstream infection (CRBSI).
   • Step 5: Bottle Inoculation: Inoculate the aerobic bottle first, followed by the anaerobic bottle (if collected); do not change needles between venipuncture and bottle inoculation (reduces needlestick injury without increasing contamination).
   • Step 6: Agitation & Labeling: Gently invert bottles 2–3 times to mix with broth and anticoagulant (sodium polyanethol sulfonate - SPS); label at bedside without covering the manufacturer’s barcode, and transport to the microbiology laboratory at room temperature immediately (do not refrigerate).

Epidemiological & Clinical Pearls for Tested Pathogens

Environmental / Zoonotic Exposure
  │
  ├─ Fresh water/aquarium contact ──────> Mycobacterium marinum (Swimming pool granuloma)
  ├─ Tropical muddy soil/water exposure ─> Burkholderia pseudomallei (Melioidosis)
  ├─ Aerosolized water cooling systems ─> Legionella pneumophila (Pontiac fever / Legionnaires')
  ├─ Sandfly (Lutzomyia) in Andes ──────> Bartonella bacilliformis (Oroya fever / Verruga peruana)
  ├─ Cat scratch / flea feces ──────────> Bartonella henselae (Peliosis / Bacillary angiomatosis)
  └─ Coxsackievirus B fecal-oral ────────> Bornholm disease (Pleurodynia / "Devil's grip")

Key Distinctive Characteristics

• Burkholderia pseudomallei (Melioidosis): Endemic in Southeast Asia and Northern Australia (and increasingly recognized along the southwest coast of India). Causes acute septicemic melioidosis, multiple splenic/hepatic "honeycomb" abscesses, and chronic cavitary pulmonary lesions resembling tuberculosis. Inherently resistant to penicillins, ampicillin, first/second-generation cephalosporins, and aminoglycosides; initial intensive phase requires IV Ceftazidime ($50\text{ mg/kg/dose}$ Q8H) or Meropenem ($25\text{ mg/kg/dose}$ Q8H) for $\ge 14$ days, followed by oral maintenance with Trimethoprim-Sulfamethoxazole for 3–6 months.
• Bartonella bacilliformis: Transmitted by the bite of Lutzomyia sandflies in high-altitude Andean valleys (Peru, Ecuador, Colombia). Manifests in two distinct biphasic stages:
  1. Acute hemic phase (Oroya fever): Severe life-threatening hemolytic anemia, high fever, and profound immunosuppression predisposing to secondary non-typhoidal Salmonella bacteremia.
  2. Chronic eruptive phase (Verruga peruana): Develops weeks to months later, characterized by nodular, vascular angiomatous skin eruptions.

1. Clinical Diagnosis:

   • Initial rash: Erythema infectiosum (Fifth disease / "Slapped cheek" syndrome).
   • Joint manifestations: Post-viral reactive arthropathy / acute polyarthritis secondary to Parvovirus B19.

2. Causative Organism & Viral Characteristics:

   • Organism: Human Parvovirus B19 (Erythrovirus genus, Parvoviridae family).
   • Structure: Non-enveloped, single-stranded DNA (ssDNA) virus with an icosahedral capsid.
   • Target cellular receptor: Blood group P antigen (globoside / tetrahexosylceramide) on erythroid progenitor cells, megakaryocytes, and endothelial cells.

3. Definitive Diagnostic Investigations:

   • Immunocompetent host: Serum Parvovirus B19-specific IgM enzyme-linked immunosorbent assay (ELISA) (positive within 7–10 days post-exposure and persists for 2–3 months).
   • Immunocompromised host / Hematologic crisis: Quantitative Parvovirus B19 DNA detection via real-time Polymerase Chain Reaction (RT-PCR) in peripheral blood or bone marrow (as antibody production is often delayed or absent).

4. Hematologic Complication & Laboratory Hallmark:

   • Complication: Transient Aplastic Crisis (TAC) secondary to temporary cessation of erythropoiesis.
   • Hallmark laboratory finding: Profound reticulocytopenia (absolute reticulocyte count $< 10{,}000/\mu\text{L}$ or reticulocyte percentage $< 0.1\%$) despite severe, acute drop in hemoglobin; bone marrow aspirate shows giant pronormoblasts (lantern cells) with absent mature erythroid precursors.

5. Management Protocol:

   • Arthropathy:
     • Supportive therapy with oral Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Oral Ibuprofen $30\text{--}40\text{ mg/kg/day}$ divided every 6 to 8 hours (maximum $2.4\text{ g/day}$) or Naproxen $10\text{--}15\text{ mg/kg/day}$ divided every 12 hours (maximum $1\text{ g/day}$) until symptom resolution (typically self-limiting over 2–4 weeks).
   • Persistent Viremia / Chronic Pure Red Cell Aplasia:
     • Intravenous Immunoglobulin (IVIG): $400\text{ mg/kg/day}$ IV infusion daily for 5 consecutive days, OR $1\text{ g/kg/day}$ IV infusion daily for 2 days.

[Parvovirus B19 Inhalation / Respiratory Transmission]
                          │
                          ▼
     [Viremic Phase (Day 5 - 10 post-exposure)]
   - High viral load in blood and nasopharynx
   - Tropism for erythroid progenitors via P antigen
   - Lysis of pronormoblasts -> Reticulocytopenia
   - Clinical: Fever, malaise, headache, contagious!
                          │
                          ▼
  [Immune-Mediated Phase (Day 14 - 21 post-exposure)]
   - Neutralizing anti-B19 IgM/IgG antibodies appear
   - Deposition of immune complexes in skin & synovium
   - Clinical: Erythema infectiosum ("slapped cheeks", lacy rash)
   - Polyarthritis / arthropathy (symmetric, small joints)
   - Virus cleared; PATIENT IS NO LONGER CONTAGIOUS

• Arthropathy Characteristics: Common in postpubertal females and adolescents (up to 50–70%), but uncommon in young children. Usually symmetric, non-erosive, self-limiting, and resolves within 2–6 weeks without long-term joint destruction.
• Special Vulnerable Populations:
  • Hemolytic anemias (Thalassemia, Sickle cell, Hereditary spherocytosis): High baseline RBC turnover leads to severe transient aplastic crisis (TAC).
  • Pregnancy: Infection during second trimester leads to severe fetal anemia, non-immune hydrops fetalis, and intrauterine fetal demise due to cardiac failure.

1. Therapeutic Regimen Architecture (NTEP / WHO Daily Regimen):

   • Intensive Phase (IP): 2 months (8 weeks / 56 daily doses) of four drugs: Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), and Ethambutol (E) [Regimen designation: 2 HRZE].
   • Continuation Phase (CP): 4 months (16 weeks / 112 daily doses) of three drugs: Isoniazid (H), Rifampicin (R), and Ethambutol (E) [Regimen designation: 4 HRE].
   • Total Duration: 6 months (168 daily doses). All doses are administered as daily, caregiver-administered, directly observed therapy.

2. Pediatric First-Line Antitubercular Drug Dosages (for 10 kg Child):

   • Isoniazid (H):
     • Target dose: $10\text{ mg/kg/day}$ (Range: $7\text{--}15\text{ mg/kg/day}$)
     • Calculated dose for $10\text{ kg}$: $\mathbf{100\text{ mg/day}}$ (Maximum daily ceiling: $300\text{ mg/day}$)
   • Rifampicin (R):
     • Target dose: $15\text{ mg/kg/day}$ (Range: $10\text{--}20\text{ mg/kg/day}$)
     • Calculated dose for $10\text{ kg}$: $\mathbf{150\text{ mg/day}}$ (Maximum daily ceiling: $600\text{ mg/day}$)
   • Pyrazinamide (Z):
     • Target dose: $35\text{ mg/kg/day}$ (Range: $30\text{--}40\text{ mg/kg/day}$)
     • Calculated dose for $10\text{ kg}$: $\mathbf{350\text{ mg/day}}$ (Maximum daily ceiling: $2000\text{ mg/day}$)
   • Ethambutol (E):
     • Target dose: $20\text{ mg/kg/day}$ (Range: $15\text{--}25\text{ mg/kg/day}$)
     • Calculated dose for $10\text{ kg}$: $\mathbf{200\text{ mg/day}}$ (Maximum daily ceiling: $1200\text{ mg/day}$)

3. Pediatric Dispersible FDC Formulations and Pill Burden (Weight Band: 8–11 kg):

   • Intensive Phase (IP - Daily for 8 weeks):
     • Dispersible FDC tablet composition: HRZ ($50\text{ mg} / 75\text{ mg} / 150\text{ mg}$) plus standalone dispersible Ethambutol ($100\text{ mg}$).
     • Daily requirement: 2 tablets of HRZ ($50/75/150$) + 2 tablets of Ethambutol ($100\text{ mg}$) once daily.
     • Delivered dose: $\text{H } 100\text{ mg} + \text{R } 150\text{ mg} + \text{Z } 300\text{ mg} + \text{E } 200\text{ mg}$ (precisely matching target therapeutic ranges).
   • Continuation Phase (CP - Daily for 16 weeks):
     • Dispersible FDC tablet composition: HR ($50\text{ mg} / 75\text{ mg}$) plus standalone dispersible Ethambutol ($100\text{ mg}$) [or dispersible HRE ($50/75/100\text{ mg}$)].
     • Daily requirement: 2 tablets of HR ($50/75$) + 2 tablets of Ethambutol ($100\text{ mg}$) once daily (or 2 tablets of 3-drug HRE FDC once daily).
     • Delivered dose: $\text{H } 100\text{ mg} + \text{R } 150\text{ mg} + \text{E } 200\text{ mg}$.

4. Procedural Counseling and Safety Checklist:

   • Administration Technique: Disperse the flavored tablets completely in $10\text{--}15\text{ mL}$ of clean drinking water or expressed breast milk. Administer on an empty stomach (1 hour before or 2 hours after a meal) to optimize rifampicin bioavailability.
   • Anticipatory Guidance on Benign Side Effects: Forewarn the family that rifampicin causes harmless reddish-orange discoloration of urine, tears, saliva, and sweat to prevent unprompted treatment interruption.
   • Hepatotoxicity Warning Signs (Red Flags): Educate parents to withhold medication immediately and seek emergent hospital evaluation if the child develops persistent vomiting, refusal of feeds, severe lethargy, abdominal pain, or icterus (yellow sclera/skin).
   • Adherence and Weight Monitoring: Emphasize absolute treatment adherence for the complete 6-month duration even if clinical symptoms completely abate within 4 weeks. Instruct the family to attend monthly follow-up for weight assessment and mandatory upward dosage adjustments as the child recovers weight.

1. Infant Feeding Guidance Based on AFASS Criteria:
   • AFASS Criteria Met (Affluent/Urban Settings): If replacement feeding is Acceptable, Feasible, Affordable, Sustainable, and Safe, exclusive commercial infant formula feeding is recommended. This completely eliminates the postnatal risk of mother-to-child transmission (MTCT) of HIV.
   • AFASS Criteria Not Met (Resource-Limited Settings): Exclusive breastfeeding (EBF) under the cover of maternal antiretroviral therapy (ART) is recommended for the first 6 months, followed by introduction of complementary foods with continued breastfeeding up to 12–24 months. Formula feeding in this setting carries a high risk of infant mortality from diarrheal disease, pneumonia, and severe acute malnutrition.
2. Mixed Feeding Definition and Risk:
   • Definition: Giving an infant breast milk along with other liquids (water, animal milk, formula, fruit juices) or solid foods before 6 months of age.
   • Pathophysiology of Contraindication: Non-human proteins and microbial contaminants in water/feeds cause micro-abrasions, mucosal inflammation, and disruption of the intestinal epithelial tight junctions in the infant gut. This facilitates the direct entry and systemic translocation of cell-free and cell-associated HIV from breast milk into mucosal dendritic cells and CD4+ T cells, significantly increasing the transmission risk compared to exclusive breastfeeding.
3. Post-Exposure Infant Antiretroviral Prophylaxis:
   • Low-Risk Infant (Mother on ART $\ge 4$ weeks before delivery with viral suppression $<1000$ copies/mL):
     • Syrup Nevirapine (NVP) daily for 6 weeks.
     • Dosing: Birth weight $<2000\text{ g}$: $2\text{ mg/kg}$ once daily; $2000–2499\text{ g}$: $10\text{ mg}$ once daily ($1\text{ mL}$); $\ge 2500\text{ g}$: $15\text{ mg}$ once daily ($1.5\text{ mL}$).
   • High-Risk Infant (Mother on ART $<4$ weeks, viral load $>1000$ copies/mL, or diagnosed intrapartum/postpartum):
     • Dual prophylaxis with daily Syrup Zidovudine (AZT) + Syrup Nevirapine (NVP) for 12 weeks (or extended to complete duration of breastfeeding if maternal viral load remains elevated).
     • AZT Dosing: Birth weight $\ge 2500\text{ g}$: $4\text{ mg/kg/dose}$ orally twice daily; $2000–2499\text{ g}$: $10\text{ mg}$ twice daily; gestational age $<35$ weeks: $1.5\text{ mg/kg/dose}$ twice daily.
4. Diagnostic Timeline and Co-trimoxazole Prophylaxis (CPT):
   • Virological Testing Schedule (HIV-1 DNA/RNA PCR):
     • Baseline: At birth (within 48 hours) for high-risk infants.
     • 6 weeks of age (first routine test for all exposed infants).
     • 6 months and 12 months of age.
     • 6 weeks after complete cessation of breastfeeding.
     • Confirmatory serology (HIV antibody ELISA/Rapid test) at 18 months of age.
   • Co-trimoxazole Preventive Therapy (CPT):
     • Initiation: Started at 6 weeks of age (Syrup Co-trimoxazole: Trimethoprim $5\text{ mg/kg}$ + Sulfamethoxazole $25\text{ mg/kg}$ once daily) for all HIV-exposed infants.
     • Cessation: Discontinued only when the infant is confirmed HIV-negative after complete cessation of breastfeeding (and infant is $>6$ weeks post-weaning) and clinically asymptomatic.

1. Validity of Statements:
   • a. True: Streptococcus pyogenes (Group A beta-hemolytic Streptococcus [GABHS]) is the classic causative organism of Type II (monomicrobial) necrotizing fasciitis, frequently complicated by Streptococcal Toxic Shock Syndrome (STSS).
   • b. False: All Staphylococcus species are catalase-positive, which differentiates them from Streptococcus species (which are catalase-negative).
   • c. False: Pseudomonas aeruginosa is an oxidase-positive, non-lactose fermenting (producing pale colonies on MacConkey agar) Gram-negative bacillus.
   • d. False: The reverse is true: Staphylococcal TSS is usually a toxigenic illness mediated by TSST-1 with positive blood cultures in $<5–15\%$ of cases; conversely, Streptococcal TSS is typically invasive with positive blood cultures in $>50–60\%$ of cases.
2. Coagulase Differentiation:
   • The coagulase test detects the enzyme coagulase, which converts fibrinogen to fibrin, causing plasma clotting.
   • Staphylococcus aureus is coagulase-positive.
   • Other staphylococci (such as S. epidermidis and S. saprophyticus) are coagulase-negative staphylococci (CoNS).
3. Primary Virulence Factor:
   • M protein: A cell surface fibrillar protein that binds plasma factor H and fibrinogen, thereby inhibiting alternative pathway complement activation, limiting C3b opsonization, and preventing phagocytosis by human neutrophils.
4. Mechanism of Methicillin Resistance & Definitive Therapy:
   • Genetic Mechanism: Acquisition of the mobile genetic element SCCmec carrying the mecA (or mecC) gene, which encodes an altered penicillin-binding protein termed PBP2a (or PBP2'). PBP2a has a remarkably low binding affinity for all beta-lactam antibiotics (penicillins, cephalosporins [except 5th generation like ceftaroline], and carbapenems), permitting peptidoglycan cell wall synthesis despite therapeutic drug concentrations.
   • Drug of Choice: Vancomycin ($15\text{ mg/kg/dose}$ IV every 6 hours, target trough $15–20\text{ mcg/mL}$) or Linezolid ($10\text{ mg/kg/dose}$ IV/oral every 8 hours in children $<12$ years).

1. Validity of Statements:
   • a. True: Staphylococcus aureus (both MSSA and MRSA) accounts for $70–80\%$ of pediatric acute hematogenous osteomyelitis cases.
   • b. False: Plain radiographs are typically normal during the first 7–10 days, showing only deep soft tissue swelling. Osseous changes (periosteal elevation, cortical lucency, and lytic demineralization) require $30–50\%$ bone mineral loss and are visible only after 10–14 days.
   • c. True: CRP peaks within 36–48 hours and has a short half-life ($19$ hours), normalizing rapidly within 7–10 days of successful therapy; ESR rises slower and remains elevated for 3–4 weeks.
   • d. False: Blood cultures are positive in only $30–50\%$ of pediatric osteomyelitis cases.
2. Metaphyseal Predilection Pathophysiology:
   • Nutrient arteries branch into non-anastomotic, hairpin capillary loops that terminate in large, non-fenestrated sinusoidal veins within the metaphysis adjacent to the epiphyseal growth plate.
   • This configuration creates a zone of turbulent, sluggish blood flow with low oxygen tension.
   • The endothelium lacks an adequate population of active lining macrophages (reticuloendothelial deficit), allowing circulating bacteria to easily adhere, colonize, and proliferate within the vascular spaces.
3. Infantile Susceptibility to Septic Arthritis:
   • In infants $<12–18$ months of age, transphyseal blood vessels cross the cartilaginous growth plate (physis), connecting the metaphyseal circulation directly to the epiphysis.
   • Bacterial infection in the metaphysis can readily propagate along these patent channels into the epiphysis and rupture through the articular surface into the joint space.
   • Beyond 18 months, resorption of transphyseal vessels and closure of this vascular communication by the physis establishes an impenetrable anatomical barrier.
4. Empirical Therapy and Oral Switch Criteria:
   • Empirical Regimen:
     • Low MRSA prevalence ($<10\%$): Cefazolin ($100–150\text{ mg/kg/day}$ IV divided every 8 hours) OR Oxacillin/Cloxacillin ($150–200\text{ mg/kg/day}$ IV divided every 6 hours).
     • High MRSA prevalence ($\ge 10\%$) or toxic/septic child: Vancomycin ($60\text{ mg/kg/day}$ IV divided every 6 hours) OR Clindamycin ($40\text{ mg/kg/day}$ IV divided every 8 hours, if local D-test resistance $<10\%$).
   • Oral Switch Criteria:
     • Afebrile for $\ge 48–72$ hours.
     • Significant improvement in localized pain, erythema, and weight-bearing ability.
     • Sustained downward trend of CRP by $>50\%$ from baseline peak.
     • Patient tolerating oral intake without vomiting and compliant caregivers available.

1. Anatomical Definition of Ghon Complex:
   • Consists of three components:
     • The Ghon focus (subpleural parenchymal granuloma, typically in the mid-to-lower zones).
     • Lymphangitis (inflamed draining lymphatic vessels).
     • Regional lymphadenopathy (enlarged ipsilateral hilar or paratracheal lymph nodes).
2. Congenital vs. Postnatally Acquired Tuberculosis:
   • Congenital Tuberculosis:
     • Transmission Route: Hematogenous dissemination via the umbilical vein from infected placenta, or aspiration/ingestion of infected amniotic fluid during parturition.
     • Primary Focus: Liver (primary complex in the hepatic parenchyma with periportal/porta hepatis lymphadenopathy) if acquired transumbilically; or lungs/gut if acquired via aspiration/swallowing of amniotic fluid.
   • Postnatally Acquired Tuberculosis:
     • Transmission Route: Airborne droplet nuclei inhaled from infectious mother or caregiver.
     • Primary Focus: Lungs (parenchymal focus with hilar/mediastinal lymphadenopathy).
3. Management Plan for Asymptomatic Neonate Born to Mother with Active TB:
   • Step 1: Clinical and Diagnostic Evaluation: Screen infant for symptoms (fever, poor feeding, respiratory distress, hepatosplenomegaly) and obtain baseline chest X-ray and gastric aspirate for CBNAAT/cartridge-based nucleic acid amplification.
   • Step 2: If Evaluation is Negative (Asymptomatic Infant):
     • Defer BCG vaccination at birth.
     • Initiate Isoniazid Preventive Therapy (IPT) at $10\text{ mg/kg/day}$ orally for 6 months (along with Pyridoxine $10\text{ mg/day}$).
     • At 6 months: Perform Mantoux (tuberculin skin test) and chest radiograph.
     • If asymptomatic and screening remains negative: Stop Isoniazid and administer BCG vaccination (minimum 2 weeks after stopping INH).
   • Step 3: Breastfeeding Guidance: Continue exclusive breastfeeding; mother should wear a well-fitted surgical mask until she is sputum smear-negative for $\ge 2$ weeks.
4. First-Line Pediatric Regimens (Daily Therapy):
   • Pediatric Pulmonary Tuberculosis:
     • Intensive Phase ($2\text{ months}$): $2\text{HRZE}$ (Isoniazid $10\text{ mg/kg}$, Rifampicin $15\text{ mg/kg}$, Pyrazinamide $35\text{ mg/kg}$, Ethambutol $20\text{ mg/kg}$ daily).
     • Continuation Phase ($4\text{ months}$): $4\text{HRE}$ or $4\text{HR}$ (Isoniazid $10\text{ mg/kg}$, Rifampicin $15\text{ mg/kg}$, Ethambutol $20\text{ mg/kg}$ daily).
   • Tuberculous Meningitis (TBM) / Spinal TB:
     • Intensive Phase ($2\text{ months}$): $2\text{HRZE}$ at high doses (Isoniazid $15–20\text{ mg/kg}$, Rifampicin $20\text{ mg/kg}$, Pyrazinamide $35–40\text{ mg/kg}$, Ethambutol $20\text{ mg/kg}$).
     • Continuation Phase ($10\text{ months}$): $10\text{HRE}$ (Total duration = 12 months).
     • Adjuvant Corticosteroids: Intravenous Dexamethasone ($0.4\text{ mg/kg/day}$) or oral Prednisolone ($2–4\text{ mg/kg/day}$) for 4 weeks, tapered over the subsequent 4 weeks.

1. Perinatal Transmission Risk & Long-Term Sequelae:
   • Transmission Risk Without Immunoprophylaxis:
     • Mother HBsAg-positive AND HBeAg-positive: $70–90\%$ risk of vertical transmission (with $>90\%$ of infected infants becoming chronic carriers).
     • Mother HBsAg-positive AND HBeAg-negative / Anti-HBe-positive: $10–30\%$ risk of transmission (with $\sim 10–15\%$ becoming chronic carriers).
   • Long-Term Sequelae: Approximately $25\%$ of infants who acquire chronic HBV infection perinatally die prematurely in adulthood from cirrhosis, end-stage liver disease, or hepatocellular carcinoma (HCC).
2. Active-Passive Immunoprophylaxis Protocol:
   • Hepatitis B Immune Globulin (HBIG):
     • Dose: $0.5\text{ mL}$ ($100–200\text{ IU}$) intramuscularly.
     • Timing: Administer within 12 hours of birth (efficacy decreases significantly if delayed beyond 24–48 hours).
     • Site: Anterolateral aspect of the left thigh.
   • Hepatitis B Monovalent Vaccine:
     • Dose: $0.5\text{ mL}$ ($10\text{ mcg}$) intramuscularly.
     • Timing: Administer within 12 hours of birth concurrently with HBIG.
     • Site: Anterolateral aspect of the right thigh (must use separate syringes and distinct anatomical sites; never mix HBIG and vaccine in the same limb).
     • Subsequent Doses: Complete remaining series at 1, 2, and 6 months (or 6, 10, 14 weeks via national pentavalent vaccine schedule).
3. Mechanisms of Immunoprophylaxis Failure:
   • High Maternal Viral Load / Intrauterine Infection: Maternal HBV DNA $>200,000\text{ IU/mL}$ ($>10^6\text{ copies/mL}$) can overwhelm circulating anti-HBs antibodies, or transmission may occur in utero prior to delivery across transplacental micro-hemorrhages, rendering post-delivery prophylaxis ineffective.
   • HBV Surface Antigen Escape Mutations: Mutations in the "a" determinant of the HBsAg gene (most classically the G145R mutation, where glycine is substituted by arginine at amino acid position 145), which alters the conformational epitope of the surface antigen, preventing neutralization by vaccine-induced antibodies or donor HBIG.
4. Post-Vaccination Serological Testing (PVST):
   • Timing of Testing: Perform testing between 9 and 12 months of age (or 1–2 months after the final dose of the primary vaccine series). Testing should not be done before 9 months to avoid detecting residual passively acquired maternal anti-HBs or injected HBIG antibodies.
   • Tests Required: Qualitative HBsAg and quantitative anti-HBs antibody titer.
   • Interpretation:
     • Protected / Non-infected: HBsAg negative AND anti-HBs $\ge 10\text{ mIU/mL}$.
     • Non-responder / Unprotected: HBsAg negative AND anti-HBs $<10\text{ mIU/mL}$ (requires a repeat 3-dose vaccine series followed by retesting).
     • Infected: HBsAg positive (indicates chronic infection; child requires referral for pediatric gastroenterology follow-up and monitoring).

graph TD
    A[Infant Born to HBsAg Positive Mother] --> B[Immediate Delivery Room Care]
    B --> C[Administer within 12 Hours of Life]
    C --> D[HBIG 0.5 mL IM in Left Anterolateral Thigh]
    C --> E[Hep B Vaccine 0.5 mL IM in Right Anterolateral Thigh]
    D & E --> F[Complete Full Vaccine Series at 6, 10, 14 Weeks or 1, 2, 6 Months]
    F --> G[Post-Vaccination Serologic Testing at 9-12 Months]
    G --> H{Serological Result}
    H -->|HBsAg (-) and Anti-HBs >= 10 mIU/mL| I[Protected: Fully Immune]
    H -->|HBsAg (-) and Anti-HBs < 10 mIU/mL| J[Non-responder: Revaccinate with 3-dose Series]
    H -->|HBsAg (+)| K[Infected: Longitudinal Pediatric GI/Hepatology Follow-up]

1. Probable Clinical Diagnosis:
   • Pertussis (whooping cough) caused by Bordetella pertussis (paroxysmal stage).
2. Confirmatory Microbiological Investigations:
   • Nasopharyngeal Swab / Aspirate for Polymerase Chain Reaction (PCR): Highest sensitivity within the first 3 to 4 weeks; targets insertion elements such as IS481. Swab material must be Dacron or calcium alginate (rayon acceptable; cotton and calcium alginate with wooden shafts inhibit PCR/culture).
   • Bacterial Culture: Gold standard for specificity. Requires transport on Regan-Lowe transport medium and primary inoculation onto specialized enriched media such as Bordet-Gengou agar (potato-blood-glycerol) or charcoal horse blood agar (Regan-Lowe agar) incubated at 35°C–37°C in high humidity for 7–12 days.
3. Characteristic Hemogram Abnormality & Pathophysiology:
   • Finding: Marked absolute lymphocytosis ($\ge 10,000/\mu\text{L}$ or $> 50\%–70\%$ of differential) often accompanied by pronounced hyperleukocytosis (total leukocyte count frequently $> 20,000$ to $50,000/\mu\text{L}$ with mature, normal-appearing lymphocytes).
   • Pathophysiology: Mediated by Pertussis Toxin (PT), an A-B subunit exotoxin that catalyzes the ADP-ribosylation of the inhibitory alpha subunit of G-proteins ($G_{\alpha i}$). This disrupts signal transduction, blocking lymphocyte extravasation and homing back into lymphoid tissues (lymph nodes and spleen), resulting in lymphocyte sequestration within the intravascular compartment.
4. Antimicrobial Regimen & Contact Prophylaxis:
   • First-Line Therapeutic Drug: Oral Azithromycin:
     • Dose: $10\text{ mg/kg/day}$ orally once daily for 5 days (maximum $500\text{ mg}$ on day 1, followed by $250\text{ mg/day}$ on days 2–5 for children $\ge 6$ months; for infants $< 6$ months: $10\text{ mg/kg/day}$ once daily for 5 days).
     • Alternative: Oral Clarithromycin $15\text{ mg/kg/day}$ divided every 12 hours for 7 days (maximum $1\text{ g/day}$).
   • Post-Exposure Chemoprophylaxis:
     • All household and close contacts regardless of age or immunization status should receive post-exposure prophylaxis with oral Azithromycin ($10\text{ mg/kg/day}$ once daily for 5 days) initiated within 21 days of cough onset in the index patient.

1. Most Likely Diagnosis:
   • Pneumocystis jirovecii pneumonia (PJP; formerly Pneumocystis carinii pneumonia / PCP).
2. Imaging Abnormalities:
   • Chest Radiograph: Bilateral, symmetric, perihilar ground-glass opacities / diffuse interstitial reticulogranular infiltrates with peripheral sparing, which may progress to diffuse alveolar consolidation.
   • High-Resolution CT (HRCT): Patchy or diffuse bilateral ground-glass opacification (GGO) with a perihilar and apicobasal gradient, crazy-paving pattern (interlobular septal thickening superimposed on GGO), and occasional thin-walled pulmonary cysts (pneumatoceles) conferring risk of spontaneous pneumothorax.
3. Definitive Microbiological Identification:
   • Silver Staining: Grocott-Gomori methenamine silver (GMS) stain (demonstrates dark brown/black round-to-cup-shaped fungal cysts with central dark spots).
   • Direct Fluorescent Antibody (DFA) staining: Using monoclonal antibodies against P. jirovecii cyst wall and trophozoites under immunofluorescence microscopy.
   • Molecular Method: Real-time quantitative Polymerase Chain Reaction (qPCR) targeting mitochondrial large-subunit rRNA or major surface glycoprotein gene in BAL fluid or induced sputum.
4. Targeted Antimicrobial & Corticosteroid Therapy:
   • First-Line Antimicrobial:
     • Intravenous Trimethoprim-Sulfamethoxazole (TMP-SMX):
     • Dosing based on Trimethoprim component: $15\text{ to }20\text{ mg/kg/day}$ of TMP (plus $75\text{ to }100\text{ mg/kg/day}$ of SMX), divided into 3 or 4 doses given every 6 to 8 hours, administered intravenously for 21 days.
   • Adjunctive Corticosteroid Protocol:
     • Indicated in moderate-to-severe disease: room air $\text{PaO}_2 < 70\text{ mmHg}$ or alveolar-arterial oxygen gradient $[\text{A-a}\ \text{DO}_2] \ge 35\text{ mmHg}$.
     • Prednisone (or IV methylprednisolone equivalent):
       • Days 1–5: $40\text{ mg}$ twice daily (or $1\text{ to }2\text{ mg/kg/day}$).
       • Days 6–10: $40\text{ mg}$ once daily (or $0.5\text{ to }1\text{ mg/kg/day}$).
       • Days 11–21: $20\text{ mg}$ once daily (or tapered to off).
     • Must be initiated before or concurrently with antimicrobial therapy to prevent post-bactericidal pulmonary inflammatory surge.

1. Criteria for Certification of Wild Poliovirus Eradication:
   • Absence of any indigenous wild poliovirus transmission for a minimum of 3 consecutive years in the presence of certification-standard surveillance.
   • Sustained high-quality Acute Flaccid Paralysis (AFP) surveillance meeting standard performance indicators:
     • Non-polio AFP rate of at least $\ge 1\text{ per }100,000$ population aged $< 15$ years in non-endemic countries ($\ge 2\text{ per }100,000$ in endemic/at-risk countries).
     • At least $\ge 80\%$ of all reported AFP cases having "adequate" stool specimens collected within 14 days of onset of paralysis, 24–48 hours apart, arriving at a WHO-accredited laboratory in reverse cold chain.
   • Maintenance of high population immunity via high routine immunization coverage ($\ge 80\%$ to $\ge 90\%$).
   • Robust national and sub-national preparedness and response plan for any imported wild or circulating vaccine-derived poliovirus (cVDPV), alongside bio-containment certification of all poliovirus-holding facilities.
2. Vaccine-Associated Paralytic Poliomyelitis (VAPP):
   • Definition: Acute flaccid paralysis that clinically resembles poliomyelitis, occurring 4 to 40 days following OPV receipt in the vaccine recipient (or 4 to 85 days in a direct contact of the recipient), with isolation of vaccine-related Sabin strain poliovirus and residual neurological weakness persisting at 60 days.
   • Risk/Incidence: Highest with the first dose of OPV, approximately 1 case per 750,000 to 1.4 million first doses administered (overall lifetime risk across all doses is $\sim 1\text{ per }2.4\text{ to }3.1\text{ million doses}$).
3. IPV Protective Effectiveness After 3 Full Doses:
   • Seroconversion/protective antibody titers:
     • Type 1 poliovirus: $> 95\%–100\%$
     • Type 2 poliovirus: $> 95\%–100\%$
     • Type 3 poliovirus: $> 95\%–100\%$
4. Fractional IPV (fIPV) Schedule Under Indian NIS:
   • Dose & Route: $0.1\text{ mL}$, Intradermal (ID).
   • Site: Right upper arm (deltoid region).
   • Ages of Administration:
     • Dose 1: At 6 weeks of age.
     • Dose 2: At 14 weeks of age.
     • Dose 3 (Booster): At 9 months of age (co-administered with MR-1).

1. WHO/NRCP Bite Category:
   • Category III Exposure: Single or multiple transdermal bites or scratches, licks on broken skin, contamination of mucous membranes with saliva, or direct contact with bats.
2. Immediate Local Wound-Care Protocol:
   • Immediate and vigorous washing and flushing of all bite wounds and surrounding skin with running tap water and soap for at least 15 minutes.
   • Application of virucidal antiseptic agents such as povidone-iodine ($5\%–10\%$) or $70\%$ ethanol.
   • Suturing is strictly avoided; if primary closure is anatomically required for hemostasis, it must be delayed for several hours after local infiltration of Rabies Immunoglobulin (RIG) and must use loose, interrupted sutures.
3. Rabies Immunoglobulin (RIG) Calculation & Administration:
   • Equine Rabies Immunoglobulin (ERIG):
     $$ > \begin{aligned} > \text{Dose} &= 40\text{ IU/kg} \times 20\text{ kg} \\ > &= \mathbf{800\text{ IU}} > \end{aligned} > $$
   • Human Rabies Immunoglobulin (HRIG):
     $$ > \begin{aligned} > \text{Dose} &= 20\text{ IU/kg} \times 20\text{ kg} \\ > &= \mathbf{400\text{ IU}} > \end{aligned} > $$
   • Administration Technique:
     • The entire calculated dose of RIG should be thoroughly infiltrated locally in and around the wound margins to anatomically saturate all lacerated tissues.
     • If the calculated volume is insufficient to infiltrate all wounds, it can be diluted in sterile normal saline ($0.9\%\ \text{NaCl}$).
     • Any residual volume left after complete wound infiltration should be injected intramuscularly at an anatomical site distant from the vaccine injection site (e.g., contralateral anterolateral thigh or deltoid).
4. Post-Exposure Prophylaxis (PEP) Vaccination Schedules:
   • Intramuscular Regimen (Updated Essen 4-Dose Schedule):
     • Day 0, Day 3, Day 7, and Day 14.
     • Dose: 1 full vial (0.5 mL or 1.0 mL per reconstituted vial depending on manufacturer) administered IM into the anterolateral thigh (infants/toddlers) or deltoid muscle (older children); gluteal region is strictly contraindicated.
   • Intradermal Regimen (Updated Thai Red Cross 2-Site Schedule):
     • Day 0, Day 3, Day 7, and Day 28.
     • Dose: $0.1\text{ mL}$ per site injected intradermally at 2 distinct anatomical sites per visit (total $0.2\text{ mL}$ per visit): right deltoid and left deltoid (or suprascapular/anterolateral thigh regions).

1. Definition, Launch Year & Strategic Significance:
   • Acronym: Reproductive, Maternal, Newborn, Child plus Adolescent Health.
   • Launch Year: 2013, under the National Health Mission (NHM).
   • Significance of "+A": Recognizes adolescence (10–19 years) as a critical developmental window that influences future adult and maternal health. It closes the lifecycle continuum by linking adolescent physical, nutritional, and reproductive well-being directly to subsequent pregnancy outcomes and newborn survival, rather than treating age cohorts in isolation.
2. Structure of the "5x5 Matrix":
   • It comprises 5 thematic life stages (columns) matched with 5 high-impact, evidence-based priority interventions per life stage (rows):
     • 1. Reproductive Health
     • 2. Maternal Health
     • 3. Newborn Health
     • 4. Child Health
     • 5. Adolescent Health
3. Quantitative Targets Under RMNCH+A Framework:
   • Infant Mortality Rate (IMR): Reduction to $\le 25\text{ per }1,000$ live births (by 2017).
   • Maternal Mortality Ratio (MMR): Reduction to $< 100\text{ per }100,000$ live births (by 2017).
   • Total Fertility Rate (TFR): Reduction to $\le 2.1$ (replacement level fertility by 2017).
4. High-Impact Interventions (Newborn & Child Pillars):
   • Newborn Health:
     • Facility-based newborn care: Special Newborn Care Units (SNCUs) at district hospitals, Newborn Stabilization Units (NBSUs) at First Referral Units (FRUs)/CHCs, and Newborn Care Corners (NBCCs) at all delivery points.
     • Home-Based Newborn Care (HBNC) delivered by ASHAs (6 visits for institutional births, 7 visits for home deliveries).
     • Kangaroo Mother Care (KMC) and feeding support for low birth weight infants.
     • Navjaat Shishu Suraksha Karyakram (NSSK) for universal basic newborn resuscitation.
   • Child Health:
     • Intensified Diarrhea Control Fortnight (IDCF) with universal promotion of Low-Osmolarity ORS and elemental Zinc supplementation for 14 days.
     • Integrated Action Plan for Pneumonia and Diarrhea (IAPPD) / SAANS initiative for childhood pneumonia detection and early amoxicillin management.
     • Rashtriya Bal Swasthya Karyakram (RBSK) for screening of 4Ds (Defects at birth, Deficiencies, Diseases, and Development delays including disability).
     • Universal Immunization Programme (UIP) strengthening and Vitamin A biannual supplementation from 9 months to 5 years.

1. Diagnosis & Etiological Agent:
   • Diagnosis: Scabies infestation.
   • Etiological Organism: Sarcoptes scabiei var. hominis (human itch mite).
2. Circle of Hebra & Clinical Variants:
   • Circle of Hebra: An imaginary anatomical distribution encompassing the classic predilection sites of scabietic burrows and lesions: interdigital web spaces, flexor aspects of wrists, elbows, anterior axillary folds, periumbilical region, buttocks, groin, and external genitalia.
   • Clinical Variants:
     • Infantile/Neonatal scabies (involves palms, soles, head, neck, and face with vesiculopustules)
     • Crusted (Norwegian) scabies (hyperkeratotic, heavily infested form seen in immunosuppressed or neurologically impaired hosts)
     • Nodular scabies (pruritic, reddish-brown persistent nodules over genitalia and axillae representing a delayed hypersensitivity response)
     • Scabies incognito (masked morphology due to prior topical corticosteroid application)
     • Bullous scabies
     • Animal-transmitted scabies (pseudoscabies)
3. Bedside Diagnostic Confirmation:
   • Skin Scraping / Burrow Ink Test: Place a drop of mineral oil on a sterile scalpel blade (No. 15) or unexcoriated burrow; gently scrape the lesion horizontally until the roof of the burrow is shaved without inducing bleeding. Transfer scrapings onto a glass slide, add 10% potassium hydroxide (KOH) or mineral oil, cover with a coverslip, and examine under light microscopy (10× and 40×).
   • Microscopic Confirmation Criteria: Identification of the adult female mite (oval, eight-legged, flattened dorsal spines), translucent oval ova, empty egg shells, or fecal pellets (scybala).
4. Therapeutic Protocol:
   • First-line Topical Agent: 5% Permethrin cream.
   • Application Protocol: Apply thoroughly from the neck down to the toes (including scalp, forehead, temples, and neck in infants and elderly), ensuring coverage under fingernails, between digits, and within the gluteal fold. Leave on for 8 to 14 hours before washing off. Repeat identical application after 7 to 14 days to eliminate newly hatched nymphs.
   • Household Contacts: All household members and intimate contacts must be treated simultaneously, regardless of the presence or absence of symptoms.
   • Environmental Decontamination: Machine-wash clothing, towels, and bed linens used within the preceding 72 hours in hot water (>=60°C) followed by hot-cycle machine drying, or seal non-washable items in airtight plastic bags for at least 72 hours (as mites desiccate and die within 2 to 3 days off the human host).

graph TD
    A[Suspected Scabies Presentation] --> B[Confirm Diagnosis: Clinical Burrow Exam / Mineral Oil Scraping]
    B --> C[Identify Variant]
    C --> D[Classical Pediatric Scabies]
    C --> E[Crusted / Norwegian Scabies]
    D --> F[Topical 5% Permethrin: Neck to Toes x 8-14 hrs; Repeat Day 7-14]
    D --> G[Treat ALL Household Contacts Concurrently]
    D --> H[Hot Wash Bedding & Clothing >60°C or Seal x 72 hrs]
    E --> I[Combined Oral Ivermectin 200 mcg/kg Days 1, 2, 8, 9, 15 + Topical Permethrin Daily x 7 Days]

1. Diagnosis & Virulence Factor:
   • Clinical Diagnosis: Scarlet fever (Scarlatina).
   • Virulence Factor: Streptococcal Pyrogenic Exotoxins (SPE-A, SPE-B, and SPE-C; previously termed erythrogenic toxins) produced by Group A beta-hemolytic Streptococcus (Streptococcus pyogenes).
2. Enanthem Evolution & Cutaneous Signs:
   • Tongue Evolution:
     • Days 1–2: White Strawberry Tongue (dorsal tongue covered with a thick white coat through which swollen, hyperemic fungiform papillae project).
     • Days 4–5: Red Strawberry Tongue (the white coat desquamates, exposing a denuded, glistening, beefy-red lingual surface with prominent, red, hyperplastic papillae).
   • Eponymic / Named Signs:
     • Pastia Lines (Pastia sign): Linear petechial streaks appearing in flexural skin folds (antecubital fossae, axillae, groin) where capillary fragility is heightened and resisting blanching.
     • Circumoral Pallor (Filatow sign): Facial flushing with distinct sparing and blanching of the skin surrounding the lips and chin.
3. Diagnostic Evaluation:
   • Throat swab for Rapid Antigen Detection Test (RADT) for Group A Streptococcus (rapid point-of-care confirmation).
   • Throat swab bacterial culture on 5% sheep blood agar (gold standard for confirming Streptococcus pyogenes).
   • Serological titers: Anti-Streptolysin O (ASO) titer and Anti-DNase B titer (useful for retrospective confirmation of recent streptococcal infection).
4. Antimicrobial Management & Prevented Sequela:
   • First-Line Therapy:
     • Oral Phenoxymethylpenicillin (Penicillin V): 250 mg PO two to three times daily for children <27 kg; 500 mg PO two to three times daily for children >=27 kg for a full duration of 10 days.
     • Alternative first-line: Oral Amoxicillin 50 mg/kg/day once daily (or divided BID; maximum 1,000 mg/day) for 10 days.
     • Injectable single-dose: Intramuscular Benzathine Penicillin G: 600,000 units IM single dose for children <27 kg; 1,200,000 units IM single dose for children >=27 kg.
   • Prevented Late Sequela: Acute Rheumatic Fever (ARF) and rheumatic heart disease (Note: Antimicrobial therapy prevents suppurative complications and ARF, but does not prevent Post-Streptococcal Glomerulonephritis [PSGN]).

1. Cutaneous Lesion, Pathogen & Vector:
   • Cutaneous Lesion: Eschar (tache noire).
   • Causative Organism: Orientia tsutsugamushi (formerly Rickettsia tsutsugamushi).
   • Vector: Larval stage of trombiculid mites (chiggers), predominantly Leptotrombidium deliense.
2. Morphology & Concealed Anatomical Sites:
   • Morphological Description: A painless, non-pruritic, punched-out ulcer with a central black, necrotic crust (resembling a cigarette burn) bordered by an indurated, erythematous halo, typically accompanied by regional lymphadenopathy.
   • Anatomical Sites of Predilection:
     • Axillary folds
     • Groin and inguinal creases
     • Perineum, scrotum, and vulvar folds
     • Retroauricular fold and posterior hairline
     • Umbilicus and waistline
3. Confirmatory Diagnostic Tests:
   • IgM ELISA for Orientia tsutsugamushi: Positive optical density (OD) value above the established regional cut-off (typically OD >= 0.5 or >= 1.0 depending on local endemic validation).
   • Indirect Immunofluorescence Assay (IFA): Considered reference serological standard; demonstrated four-fold or greater rise in reciprocal antibody titers between acute and convalescent sera, or a single high titer >= 1:64.
   • Polymerase Chain Reaction (PCR): Detection of the 56-kDa type-specific antigen or 47-kDa outer membrane protein gene from whole blood (buffy coat) or eschar biopsy/crust swab.
4. Pharmacological Management:
   • Drug of Choice: Oral or Intravenous Doxycycline.
     • Dose: 4.5 mg/kg/day divided every 12 hours (maximum 200 mg/day).
     • Duration: 7 to 10 days (or minimum 48 hours after complete defervescence). Doxycycline is the first-line therapy across all pediatric age groups for rickettsial infections without risk of dental staining when used in short courses.
   • Alternative Agent: Oral or Intravenous Azithromycin: 10 mg/kg/day once daily (maximum 500 mg/day) for 5 days (preferred in pregnancy, severe macrolide-susceptible endemic regions, or severe doxycycline allergy).

1. Hemodynamic Classification & WHO 2009 Staging:
   • Hemodynamic State: Compensated Shock (tachycardia, prolonged CRT >2 seconds, weak pulses, cool peripheries, but preserved systolic blood pressure with narrowed pulse pressure).
   • WHO 2009 Classification: Severe Dengue (manifesting with severe plasma leakage leading to compensated dengue shock syndrome, severe thrombocytopenia, and hemoconcentration).
2. Hemodynamic & Hematocrit Calculations:
   • Pulse Pressure (PP):
     $$ > \begin{aligned} > \text{Pulse Pressure} &= \text{Systolic Blood Pressure} - \text{Diastolic Blood Pressure} \\ > &= 92 - 72 \\ > &= \mathbf{20 \text{ mmHg}} \quad (\text{Significant narrowing: } \le 20 \text{ mmHg defines shock in dengue}) > \end{aligned} > $$
   • Percentage of Hemoconcentration:
     $$ > \begin{aligned} > \text{Hemoconcentration } (\%) &= \frac{\text{Current Hct} - \text{Baseline Hct}}{\text{Baseline Hct}} \times 100 \\ > &= \frac{46 - 34}{34} \times 100 \\ > &= \frac{12}{34} \times 100 \\ > &= \mathbf{35.29\%} \quad (>20\% \text{ confirms severe plasma leakage}) > \end{aligned} > $$
3. Emergency Fluid Resuscitation Protocol:
   • Fluid Choice: Isotonic crystalloid solution (Ringer’s Lactate or 0.9% Normal Saline).
   • Initial Resuscitation Rate: Administer 5 to 10 mL/kg/hour over the first 1 hour.
     • For this 16 kg child at 7 mL/kg/hr:
       $$ > \text{Fluid Volume} = 16 \text{ kg} \times 7 \text{ mL/kg/hr} = \mathbf{112 \text{ mL/hr over the 1st hour}} > $$
   • Titration Algorithm:
     • If patient improves (pulse pressure widens >20 mmHg, CRT <2 sec, HR normalizes, urine output >=1 mL/kg/hr): Step-down crystalloid rate sequentially:
       • Reduce to 5–7 mL/kg/hr for 1–2 hours (80–112 mL/hr).
       • Reduce to 3–5 mL/kg/hr for 2–4 hours (48–80 mL/hr).
       • Reduce to 2–3 mL/kg/hr for 24–48 hours, tapering to maintenance.
     • If shock persists or worsens and Hematocrit remains elevated: Administer a second bolus of isotonic crystalloid or colloid (10–20 mL/kg over 30–60 minutes, e.g., 10% Dextran 40 or 6% Hydroxyethyl starch).
     • If shock persists and Hematocrit abruptly plummets: Suspect hidden internal hemorrhage; urgently crossmatch and transfuse 10 mL/kg of fresh packed red blood cells (or 20 mL/kg of fresh whole blood).
4. Criteria to Discontinue Intravenous Fluids:
   • Hemodynamic stability with warm extremities, CRT <2 seconds, normal pulse rate, and normal blood pressure with wide pulse pressure (>20 mmHg).
   • Stable, decreasing hematocrit around baseline value in the presence of stable vitals.
   • Adequate spontaneous urine output (>=1 to 1.5 mL/kg/hour).
   • Resolution of fever for >=48 hours without antipyretics and recovery of appetite.
   • Absence of respiratory distress or fluid overload signs (pulmonary edema, large pleural effusion, tense ascites).

graph TD
    A

1. Diagnosis and Classification:

   • Diagnosis: Stevens-Johnson Syndrome (SJS).
   • Classification by Epidermal Detachment (BSA):
     • Stevens-Johnson Syndrome (SJS): < 10% BSA epidermal detachment with widespread purpuric macules/atypical targets.
     • SJS / Toxic Epidermal Necrolysis (TEN) Overlap: 10% to 30% BSA epidermal detachment.
     • Toxic Epidermal Necrolysis (TEN): > 30% BSA epidermal detachment (with or without spots).

2. Etiology:

   • Pharmacological Triggers (most common cause, 80–90%):
     • Aromatic Anticonvulsants: Carbamazepine, Phenytoin, Phenobarbital (strongly linked to HLA-B15:02 and HLA-A31:01).
     • Antibacterials: Sulfonamides (Trimethoprim-sulfamethoxazole), Aminopenicillins, Cephalosporins, Fluoroquinolones.
     • Other high-risk agents: Allopurinol (HLA-B*58:01), Oxicam NSAIDs (Piroxicam, Meloxicam).
   • Infectious Triggers:
     • Mycoplasma pneumoniae (most common pediatric infectious trigger, causing classic M. pneumoniae-induced rash and mucositis / MIRM or reactive infectious mucocutaneous eruption / RIME).

3. Prognostic Scoring (SCORTEN):

   • Scoring System: SCORTEN (Score of Toxic Epidermal Necrolysis), evaluated within the first 24–48 hours across 7 independent clinical variables:
     • Age > 40 years
     • Heart rate ≥ 120 beats/min
     • History of malignancy
     • BSA epidermal detachment > 10% at day 1
     • Serum urea > 10 mmol/L (> 28 mg/dL)
     • Serum glucose > 14 mmol/L (> 252 mg/dL)
     • Serum bicarbonate < 20 mmol/L (< 20 mEq/L)
   • Mortality Calculation:
     $$ > \begin{aligned} > \text{SCORTEN Score} &= \mathbf{3} \\ > \text{Predicted Mortality Rate} &= \mathbf{35.3\%} \quad (\text{95\% CI: 19.7--54.5\%}) > \end{aligned} > $$
     (Reference risk profile: Score 0–1 = 3.2%; Score 2 = 12.1%; Score 3 = 35.3%; Score 4 = 58.3%; Score ≥ 5 = 90.0%).

4. Management Protocol:

   • Immediate Discontinuation: Stop all non-essential and potential culprit medications immediately (early withdrawal reduces mortality).
   • Supportive Care Environment: Transfer to a Pediatric Intensive Care Unit (PICU) or dedicated Burn Care Unit; isolate in a thermoneutral environment (ambient temperature 30–32°C) to prevent hypothermia and insensible heat loss.
   • Fluid Resuscitation:
     • Crystalloid infusion (Ringer's Lactate) calculated at $2\text{ mL/kg} \times \% \text{BSA detached}$ over the first 24 hours (in addition to baseline maintenance fluids), titrated dynamically to maintain urine output $\ge 1.0\text{ mL/kg/hour}$.
   • Wound and Mucosal Care:
     • Non-adherent, silicone- or petrolatum-impregnated dressings (e.g., Mepitel, Aquacel Ag). Contraindicated: Silver sulfadiazine (cross-reactivity with sulfonamides).
     • Daily ophthalmological evaluation with aggressive preservative-free artificial tears (hourly) and glass rod lysis of conjunctival fornices to prevent symblepharon/ankyloblepharon.
     • Mouth care with saline/chlorhexidine rinses and topical lip lubricants; genital barrier creams to prevent vaginal/urethral synechiae.
   • Immunomodulatory Therapy:
     • Intravenous Immunoglobulin (IVIG): Total dose $2\text{ to }3\text{ g/kg}$ IV divided equally over 2 to 3 days (blocks Fas-FasL-mediated keratinocyte apoptosis); OR
     • Cyclosporine A: $3\text{ to }5\text{ mg/kg/day}$ IV or PO divided q12h for 7 to 10 days, followed by tapering over 14 days; OR
     • Systemic Corticosteroids: IV Methylprednisolone $1\text{ to }2\text{ mg/kg/day}$ (or high-dose pulse: $20\text{ to }30\text{ mg/kg/day}$ max 1000 mg for 3 consecutive days) if administered within the hyperacute phase (< 48 hours of onset).

graph TD
    A[Offending Drug Exposure e.g., Carbamazepine] --> B[Drug-MHC Class I Presentation on HLA Allele]
    B --> C[Activation of CD8+ Cytotoxic T Cells & NK Cells]
    C --> D[Massive Secretion of Cytokines: Granulysin, FasL, Perforin]
    D --> E[Apoptosis of Basal Keratinocytes]
    E --> F[Full-Thickness Epidermal Detachment & Mucosal Sloughing]
    F --> G[SJS <10% BSA | Overlap 10-30% BSA | TEN >30% BSA]

1. Parasite Identification & Transmission:
   • Organism: Strongyloides stercoralis, Rhabditiform larva (L1 stage).
   • Route of transmission: Transcutaneous penetration of intact skin by infective filariform larvae (L3 stage) from contaminated soil, followed by venous-pulmonary migration; also autoinfection (internal or external perianal autoinfection).
2. Morphological Differentiation from Hookworm Rhabditiform Larvae:
   • Buccal cavity: S. stercoralis possesses a distinctly short buccal cavity (vestibule) (less than half the width of the larval head), whereas hookworm larvae feature a long buccal cavity (equal to or greater than the larval width).
   • Genital primordium: S. stercoralis exhibits a prominent, large, oval genital primordium located at the mid-body, whereas hookworm larvae have an inconspicuous or tiny genital primordium.
   • (Alternative) Esophagus: S. stercoralis has a rhabditiform esophagus extending approximately one-third of the body length.
3. Risk Factors & Eosinophil Paradox:
   • High-risk conditions:
     • Systemic corticosteroid therapy (blunts eosinophil- and Th2-mediated killing; steroids also act like ecdysteroids, accelerating larval molting).
     • Human T-cell lymphotropic virus type 1 (HTLV-1) co-infection (causes IFN-$\gamma$ diversion, suppressing IL-4 and IL-5).
     • Hematologic malignancies (e.g., leukemia, lymphoma).
     • Solid organ or hematopoietic stem cell transplantation.
     • Severe protein-energy malnutrition (marasmus / kwashiorkor).
   • Hematological paradox: Disseminated hyperinfection is frequently accompanied by a normal or suppressed eosinophil count (eosinopenia) rather than eosinophilia; absence of eosinophilia in severe infection signifies immune paralysis and carries a poor prognosis.
4. Pharmacotherapy:
   • Uncomplicated Intestinal Infection:
     • Ivermectin: $200\,\mu\text{g/kg/dose}$ orally once daily for 2 consecutive days.
     • (Alternative) Albendazole: $400\text{ mg}$ orally twice daily for 3 consecutive days (substantially lower eradication efficacy).
   • Hyperinfection Syndrome / Dissemination:
     • Ivermectin: $200\,\mu\text{g/kg/day}$ orally (or per rectum/subcutaneously in compassionate-use off-label protocols if paralytic ileus is present) daily until stool and/or sputum remain negative for larvae for at least 14 consecutive days (covering two autoinfective lifecycles).
     • Combine with broad-spectrum empirical intravenous antibiotics (e.g., Ceftriaxone or Meropenem) to treat enteric Gram-negative bacterial bacteremia or meningitis transported by migrating larvae.

graph TD
    A[Filariform L3 Larvae in Soil] -->|Transcutaneous penetration| B[Venous Circulation to Lungs]
    B -->|Alveolar rupture & ascent| C[Trachea & Swallowed into GI Tract]
    C -->|Adult female in duodenal mucosa| D[Parthenogenetic Egg Deposition]
    D -->|Hatch in gut lumen| E[Rhabditiform L1 Larvae in Stool]
    E -->|Accelerated molting in gut lumen: Steroids / Immunosuppression| F[Autoinfection: Filariform L3]
    F -->|Penetrates bowel wall or perianal skin| G[Hyperinfection Syndrome & Enteric Bacteremia]

Larva currens (racing larva) represents a pathognomonic cutaneous manifestation characterized by an urticarial, serpiginous creeping eruption advancing rapidly (up to $5\text{ to }10\text{ cm/hour}$) along the buttock, perineum, or trunk.

1. Post-Exposure Prophylaxis Assessment & Booster Schedule:
   • Tetanus toxoid vaccine (Td): Not indicated at present. The wound is contaminated ("dirty"), but the child has documented completion of a full primary series plus two boosters, and the last booster was administered 3 years ago ($<5\text{ years}$ interval).
   • Human Tetanus Immune Globulin (HTIG): Not indicated. (HTIG is indicated only if $<3$ prior doses have been received or the vaccination status is unknown/uncertain in contaminated wounds).
   • Subsequent routine boosters: Under the National Immunization Schedule (NIS) and Indian Academy of Pediatrics (IAP):
     • Tetanus and adult Diphtheria (Td) at 10 years of age.
     • Td booster at 16 years of age, followed by routine decennial (every 10 years) boosters throughout adulthood.
2. Neonatal Diagnosis & Bedside Screening:
   • Clinical diagnosis: Neonatal Tetanus (Tetanus neonatorum).
   • Bedside test: Spatula Test.
   • Execution & response: The posterior pharyngeal wall is gently touched with a sterile, soft-tipped spatula or tongue depressor. A positive test is marked by reflex spasm of the masseter muscles causing the infant to bite down on the spatula (in contrast to a normal negative test, which elicits a gag reflex and an attempt to expel the instrument).
3. Molecular Pathophysiology:
   • Toxin: Tetanospasmin (a $150\text{ kDa}$ zinc-dependent metalloproteinase AB-toxin synthesized by Clostridium tetani).
   • Transport: Internalized at neuromuscular junctions into alpha-motor neurons; undergoes retrograde intra-axonal transport along motor axons via dynein motors to the cell bodies in the spinal cord and brainstem, transiting trans-synaptically into inhibitory presynaptic interneurons (Renshaw cells).
   • Intracellular target: Light-chain metalloproteinase selectively cleaves Synaptobrevin-2 (also termed Vesicle-Associated Membrane Protein, VAMP), a core SNARE protein.
   • Consequence: Irreversible blockade of exocytic vesicle release of inhibitory neurotransmitters (GABA and glycine), resulting in unopposed, simultaneous motor neuron excitation (causing rigidity and reflex spasms) and profound autonomic sympathetic disinhibition.
4. Comprehensive Neonatal Treatment Protocol:
   • Wound management: Thorough surgical debridement and cleansing of the umbilical stump with hydrogen peroxide or normal saline; debridement must be delayed until after passive antitoxin administration to prevent intra-procedural systemic toxin dissemination.
   • Neutralization of unbound toxin:
     • Human Tetanus Immune Globulin (HTIG): $500\text{ IU}$ IM single dose (equally efficacious to higher doses; infiltrate part around the umbilicus if feasible).
     • (Alternative if HTIG unavailable) Equine Tetanus Antitoxin (TAT): $10,000\text{ to }20,000\text{ IU}$ IM/IV after a negative intradermal sensitivity test.
   • Eradication of vegetative organisms:
     • Metronidazole: $30\text{ mg/kg/day}$ IV divided every 6 to 8 hours for 7 to 10 days (preferred over penicillin G, which is a competitive GABA-A receptor antagonist and may exacerbate neuroexcitation).
   • Control of spasms and autonomic instability:
     • Diazepam: Continuous IV infusion ($0.5\text{ to }2\text{ mg/kg/hour}$) or titrated intermittent doses ($0.1\text{ to }0.3\text{ mg/kg/dose}$ every 2–4 hours).
     • Supportive isolation in a dark, quiet, stimulus-free room; early endotracheal intubation and mechanical ventilation with neuromuscular blockade (e.g., Vecuronium infusion) if severe laryngospasm or apnea supervenes.
     • Active immunization with Pentavalent/DTwP upon recovery (clinical disease confers zero immunity).

1. Diagnosis & CDC Case Definition Criteria:
   • Diagnosis: Staphylococcal Toxic Shock Syndrome (TSS).
   • CDC Criteria (all 6 categories required for a confirmed case):
     • Fever: Body temperature $\ge 38.9^\circ\text{C}$ ($102^\circ\text{F}$).
     • Rash: Diffuse macular erythroderma.
     • Desquamation: Occurs 1 to 2 weeks after illness onset, particularly affecting palms and soles.
     • Hypotension: Systolic blood pressure $\le 90\text{ mm Hg}$ for adults or $<5\text{th}$ percentile for age in children, or orthostatic syncope.
     • Multisystem involvement ($\ge 3$ of the following organ systems):
       • Gastrointestinal: Vomiting or severe diarrhea at onset.
       • Muscular: Severe myalgias or serum creatine kinase (CK) $\ge 2\times$ upper limit of normal.
       • Mucous membrane: Vaginal, oropharyngeal, or conjunctival hyperemia.
       • Renal: Serum urea nitrogen or creatinine $\ge 2\times$ upper limit of normal, or pyuria ($\ge 5\text{ WBC/HPF}$) without infection.
       • Hepatic: Total bilirubin, AST, or ALT $\ge 2\times$ upper limit of normal.
       • Hematologic: Thrombocytopenia (platelets $<100,000/\mu\text{L}$).
       • Central Nervous System: Encephalopathy / disorientation without focal neurologic signs when fever and hypotension are absent.
     • Negative laboratory results: Negative blood, throat, or CSF cultures for other pathogens (blood culture positive

1. Standard Antigen and Dosing:

   • Antigen formulation: Purified Protein Derivative (PPD) RT-23 with Tween 80.
   • Dose: 2 Tuberculin Units (TU) (equivalent to 5 TU of PPD-S standard).
   • Volume: Exactly 0.1 mL administered via a dedicated 1 mL tuberculin syringe.

2. Administration Technique:

   • Anatomical site: Volar (ventral) aspect of the forearm (conventionally left forearm), 5 to 10 cm (2 to 4 inches) distal to the elbow crease, avoiding veins, scars, or dermatitis.
   • Route: Strictly intradermal (ID) using a 26-gauge or 27-gauge short-bevel needle.
   • Bevel orientation: Bevel facing upward at an insertion angle of $5^\circ$ to $15^\circ$.
   • Immediate cutaneous sign: Formation of a pale, discrete, elevated wheal with visible follicular pit markings (peau d'orange appearance) measuring 6 to 10 mm in diameter.

3. Reading Protocol and Measurement Technique:

   • Time window: Read between 48 and 72 hours post-injection (valid up to 96 hours if delayed).
   • Parameter measured: Transverse diameter (perpendicular to the long axis of the forearm) of induration (palpable firm swelling), NOT erythema.
   • Delineation method: Sokal's ballpoint pen method (drawing a line with a medium ballpoint pen from 2 cm outside towards the induration until resistance is met; repeated from the opposite side; the distance between the two pen stops represents the induration margins measured with a transparent millimeter ruler).

4. Diagnostic Cut-Off and False-Negative Causes:

   • Cut-off for positivity: $\ge 5\text{ mm}$ of induration (qualifies as positive due to close/household contact with an active, smear-positive pulmonary tuberculosis case; also applies to HIV-infected or severely malnourished children).
   • Causes of false-negative results (anergy/suppressed delayed-type hypersensitivity):
     • Severe systemic malnutrition (e.g., severe acute malnutrition / edematous kwashiorkor).
     • Concurrent viral infections (e.g., measles, mumps, varicella, acute cytomegalovirus).
     • Disseminated, miliary, or severe forms of active tuberculosis (tuberculin anergy).
     • Immunosuppressive therapy (e.g., systemic corticosteroids $\ge 2\text{ mg/kg/day}$ for $\ge 2$ weeks, biologics/TNF inhibitors, cytotoxic chemotherapy).
     • Primary immunodeficiency diseases affecting T-cell function (e.g., SCID, DiGeorge syndrome).

Note: Prior BCG vaccination is not a contraindication to TST and should not alter the clinical interpretation of a positive induration in a symptomatic child or a known household contact.

1. Diagnosis and Critical Exposure Window:

   • Diagnosis: Neonatal Varicella (Perinatal Varicella).
   • High-Risk Window: Maternal varicella rash onset between 5 days before delivery and 2 days after delivery.
   • Pathophysiologic rationale: The neonate receives a large transplacental viral inoculum during maternal viremia without having acquired protective transplacental maternal IgG antibodies (which require roughly 5 days to synthesize and cross the placenta).

2. Systemic Complications across 4 Organ Systems:

   • Pulmonary: Varicella pneumonitis, acute respiratory distress syndrome (ARDS), secondary bacterial pneumonia.
   • Neurologic: Encephalitis, aseptic meningitis, ventriculitis, seizures.
   • Hematologic: Disseminated intravascular coagulation (DIC), severe thrombocytopenia, purpura fulminans, extensive hemorrhagic cutaneous lesions.
   • Gastrointestinal / Hepatic: Acute necrotizing hepatitis, fulminant hepatic failure, necrotizing enterocolitis.

3. Diagnostic Evaluation:

   • Bedside Test: Tzanck smear of vesicle base scraping (stained with Wright or Giemsa) demonstrating multinucleated giant cells and epithelial cells with intranuclear inclusion bodies (Cowdry A inclusions).
   • Confirmatory Test: Varicella-Zoster Virus (VZV) Real-Time Polymerase Chain Reaction (RT-PCR) from vesicular fluid or scraping (gold standard with highest sensitivity and specificity).

4. Treatment and Post-Exposure Prophylaxis:

   • Definitive Treatment:
     • Intravenous Acyclovir: $20 \text{ mg/kg/dose}$ IV every 8 hours ($60 \text{ mg/kg/day}$), infused slowly over 1 hour.
     • Duration: 10 to 14 days (extend to 21 days if central nervous system or disseminated multiorgan involvement is confirmed).
   • Post-Exposure Immunoprophylaxis (at delivery):
     • Varicella Zoster Immune Globulin (VariZIG): $125 \text{ IU}$ (1 vial) administered intramuscularly (IM) as a single dose as soon as possible after delivery (effective if given within 96 hours; licensed for use up to 10 days post-exposure).

Spectrum of Perinatal Varicella-Zoster Virus Infections

Decision Algorithm for Neonatal Exposure

• Maternal onset $> 5$ days prior to delivery: Infant has acquired maternal IgG transplacentally; disease is usually mild if it develops. Monitor closely; administer IV acyclovir only if lesions appear.
• Maternal onset $\le 5$ days prior to 2 days after delivery: Infant lacks maternal IgG. Administer VariZIG 125 IU IM immediately. If clinical lesions emerge despite prophylaxis, initiate therapeutic IV Acyclovir ($20 \text{ mg/kg/dose}$ q8h).
• Premature infants born $\ge 28$ weeks: Administer VariZIG if mother has no history of immunity.
• Premature infants born $< 28$ weeks or $< 1000 \text{ g}$: Administer VariZIG regardless of maternal history due to inadequate transplacental IgG transfer before the third trimester.

1. Microscopic Structure & Stage:
   • Leishman-Donovan (LD) bodies.
   • Amastigote form (intracellular non-flagellated round-to-oval bodies, 2–4 µm in diameter, within reticuloendothelial macrophages; characterized by a spherical nucleus and a rod-shaped kinetoplast).
2. Culture Medium & In Vitro Form:
   • Novy-MacNeal-Nicolle (NNN) biphasic culture medium (composed of rabbit blood agar overlayed with physiological saline).
   • Promastigote form (spindle-shaped, motile, flagellated form with a single anterior flagellum).
3. Insect Vector:
   • Female sandfly: Phlebotomus argentipes.
4. Definitive Treatment Protocol:
   • Liposomal Amphotericin B (AmBisome): Single intravenous infusion of 10 mg/kg administered over 2 hours diluted in 5% dextrose.
5. Cutaneous Sequela & Epidemiological Significance:
   • Post-Kala-Azar Dermal Leishmaniasis (PKDL).
   • Epidemiological significance: Acts as the primary anthroponotic reservoir host for Leishmania donovani during inter-epidemic periods, maintaining transmission in the community because nodular and macular lesions harbor high densities of parasites accessible to biting sandflies.

flowchart TD
    A[Infected Sandfly Bites Host] -->|Inoculates Promastigotes| B[Phagocytosed by Tissue Macrophages]
    B -->|Transform within Phagolysosome| C[Amastigotes / LD Bodies]
    C -->|Asexual Binary Fission| D[Macrophage Rupture & Systemic Dissemination]
    D --> E[Reticuloendothelial System Tropism]
    E --> F[Massive Splenomegaly & Hepatomegaly]
    E --> G[Bone Marrow Infiltration: Pancytopenia]
    E --> H[Polyclonal B-Cell Activation: Hypergammaglobulinemia]

Key Clinical Pearls:

• Visceral leishmaniasis (Kala-Azar, "black fever") causes cutaneous hyperpigmentation secondary to cytokine-mediated stimulation of melanocytes.
• Marked hypergammaglobulinemia with reversal of the Albumin:Globulin (A:G) ratio is characteristic, formerly screened via the Napier's Aldehyde test and Chopra's Antimony test.
• Diagnostic sensitivity of aspirates: Splenic aspirate (>95%) > Bone marrow aspirate (60–85%) > Lymph node aspirate (50%). Splenic aspiration carries a higher risk of fatal hemorrhage and requires a normal prothrombin time and platelet count >40,000/mm³.

1. Definitive Diagnosis & Smear Findings:
   • Visceral Leishmaniasis (Kala-Azar) with secondary pancytopenia.
   • Smear demonstrates intracellular and extracellular Leishmania donovani amastigotes (LD bodies) within reticuloendothelial histiocytes/macrophages.
2. Rapid Immunochromatographic Diagnostic Test:
   • rK39 strip test (rapid immunochromatographic dipstick assay).
   • Detects circulating IgG antibodies directed against the recombinant K39 antigen (a 39-amino-acid repeat of a kinesin-like protein of Leishmania donovani).
3. Therapeutic Dose Calculation:
   $$ > \begin{aligned} > \text{Drug} &= \text{Liposomal Amphotericin B} \\ > \text{Weight-based Dose} &= 10\text{ mg/kg (single dose)} \\ > \text{Calculated Total Dose} &= 18\text{ kg} \times 10\text{ mg/kg} = \mathbf{180\text{ mg}} \\ > \text{Route \& Administration} &= \text{Intravenous infusion over 2 hours} \\ > \text{Compatible Diluent} &= 5\%\text{ Dextrose Injection only (incompatible with normal saline)} > \end{aligned} > $$
4. Alternative Pharmacotherapeutic Regimens:
   • Miltefosine: Oral alkylphosphocholine; for children aged 2–11 years, 2.5 mg/kg/day divided twice daily for 28 days.
   • Paromomycin sulfate: Aminoglycoside; 15 mg/kg/day (equivalent to 11 mg/kg/day base) intramuscularly once daily for 21 days.
   • Combination therapy: Single-dose Liposomal Amphotericin B (5 mg/kg IV) combined with Miltefosine (oral for 7 days) OR Paromomycin (IM for 10 days).
5. Pathophysiological Mechanisms of Pancytopenia:
   • Hypersplenism: Marked splenic reticuloendothelial hyperplasia causing pathological sequestration and accelerated mechanical destruction of circulating erythrocytes, leukocytes, and platelets.
   • Bone Marrow Suppression: Massive infiltration and crowding of marrow hematopoietic niches by multiplying, infected histiocytes.
   • Hemophagocytosis & Immune Destruction: Chronic immune hyperactivation with secondary hemophagocytic lymphohistiocytosis (sHLH) and autoimmune-mediated peripheral destruction (anti-erythrocyte/platelet autoantibodies).

rK39 Serology Caveats:

• rK39 has >98% sensitivity and >90% specificity in the Indian subcontinent.
• It remains positive for months to years following parasitological cure; therefore, rK39 cannot be utilized as a test of cure or to diagnose relapses. Relapses must be confirmed by repeat bone marrow or splenic aspiration demonstration of amastigotes.